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Supplementary Figures 
 
 
 
 
 
 
 
 
Supplementary Figures 1(a) and (b). Comparison of nickel-catalyzed reductive coupling method and 
base-mediated amidation of esters with anilines. Et = ethyl; Me = methyl; THF = tetrahydrofuran; KOt-
Bu = potassium tert-butoxide.  
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Supplementary Figure 2. Application in synthesis of the key intermediate of an antipsychotic drug. 
Lit. = reported yield from literature; Me = methyl; Al(Oi-Pr)3 = aluminum isopropoxide. EDC = N-
ethyl-N′-(3-dimethylaminopropyl)carbodiimide; HOBt = 1-hydroxybenzotriazole.  
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Supplementary Figures 3(a)-(c). Study of relationship between steric bulkiness of esters and relative 
reactivity of amidation. 
1
H NMR yields were shown. The ratios of amide products were determined by 
1
H NMR spectrometry. Me = methyl; t-Bu = tert-butyl.  
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Supplementary Figure 4. 
1
H and 
13
C NMR spectra of Methyl 5-(4-Chloro-3,5-
dimethylphenoxy)pentanoate (S1) 
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Supplementary Figure 5. 
1
H and 
13
C NMR spectra of Methyl 5-Morpholinopentanoate (S2) 
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Supplementary Figure 6. 
1
H and 
13
C NMR spectra of Methyl 6-Morpholino-6-
oxohexanoate (S3) 
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Supplementary Figure 7. 
1
H and 
13
C NMR spectra of Methyl 6-(Cyclohexylamino)-6-
oxohexanoate (S4) 
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Supplementary Figure 8. 
1
H and 
13
C NMR spectra of Methyl 6-((1-(4-Fluorophenyl)-1H-
indazol-5-yl)amino)-6-oxohexanoate (S5) 
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Supplementary Figure 9. 
1
H and 
13
C NMR spectra of Pentyl 2-((4-Methoxy-2-
nitrophenyl)thio)benzoate (S6) 
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Supplementary Figure 10. 
1
H and 
13
C NMR spectra of N-(4-(tert-Butyl)phenyl)decanamide (3a) 
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Supplementary Figure 11. 
1
H and 
13
C NMR spectra of N-(4-Methoxyphenyl)decanamide (3b) 
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Supplementary Figure 12. 
1
H and 
13
C NMR spectra of N-(4-(Methylthio)phenyl)decanamide (3c) 
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Supplementary Figure 13. 
1
H and 
13
C NMR spectra of N-(3-Bromo-4-methylphenyl)decanamide 
(3d) 
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Supplementary Figure 14. 
1
H and 
13
C NMR spectra of N-(3-Chloro-4-
methoxyphenyl)palmitamide (3e) 
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Supplementary Figure 15. 
1
H and 
13
C NMR spectra of N-(4-(1H-Pyrrol-1-yl)phenyl)decanamide 
(3f) 
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Supplementary Figure 16. 
1
H and 
13
C NMR spectra of N-(4-(1H-Pyrazol-1-yl)phenyl)decanamide 
(3g) 
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Supplementary Figure 17. 
1
H and 
13
C NMR spectra of N-(Quinolin-6-yl)decanamide (3h) 
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Supplementary Figure 18. 
1
H and 
13
C NMR spectra of N-(2-Methylbenzo[d]thiazol-6-
yl)decanamide (3i) 
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Supplementary Figure 19. 
1
H and 
13
C NMR spectra of N-(2-Phenylbenzo[d]oxazol-5-
yl)decanamide (3j) 
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Supplementary Figure 20. 
1
H and 
13
C NMR spectra of N-(1-Methyl-1H-indol-5-yl)decanamide 
(3k) 
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Supplementary Figure 21. 
1
H and 
13
C NMR spectra of N-(Dibenzo[b,d]thiophen-3-yl)decanamide 
(3l) 
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Supplementary Figure 22. 
1
H and 
13
C NMR spectra of (E)-3-Phenyl-N-(4-
styrylphenyl)propanamide (3m) 
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Supplementary Figure 23. 
1
H and 
13
C NMR spectra of N-(Benzo[d][1,3]dioxol-5-yl)undec-10-
enamide (3n) 
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Supplementary Figure 24. 
1
H and 
13
C NMR spectra of N-Phenyloleamide (3o) 
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Supplementary Figure 25. 
1
H and 
13
C NMR spectra of 3-((4-(tert-Butyl)phenyl)ethynyl)-N-(p-
tolyl)cyclohexane-1-carboxamide (3p) 
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Supplementary Figure 26. 
1
H and 
13
C NMR spectra of N-(4-(tert-Butyl)phenyl)-7-
chloroheptanamide (3q) 
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Supplementary Figure 27. 
1
H and 
13
C NMR spectra of N-(4-(tert-Butyl)phenyl)-5-
morpholinopentanamide (3r) 
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Supplementary Figure 28. 
1
H and 
13
C NMR spectra of N-(4-(tert-Butyl)phenyl)-3-(2-
hydroxyphenyl)propanamide (3s) 
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Supplementary Figure 29. 
1
H and 
13
C NMR spectra of 5-(4-Chloro-3,5-dimethylphenoxy)-N-(p-
tolyl)pentanamide (3t) 
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Supplementary Figure 30. 
1
H and 
13
C NMR spectra of 5-(3-Cyanophenoxy)-N-(p-
tolyl)pentanamide (3u) 
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Supplementary Figure 31. 
1
H and 
13
C NMR spectra of 5-Oxo-5-phenyl-N-(p-tolyl)pentanamide 
(3v)  
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Supplementary Figure 32. 
1
H and 
13
C NMR spectra of Methyl 4-(2-Oxo-2-(p-
tolylamino)ethyl)benzoate (3w) 
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Supplementary Figure 33. 
1
H and 
13
C NMR spectra of N-(4-(tert-Butyl)phenyl)-6-morpholino-6-
oxohexanamide (3x) 
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Supplementary Figure 34. 
1
H and 
13
C NMR spectra of N
1
-(4-(tert-Butyl)phenyl)-N
6
-
cyclohexyladipamide (3y) 
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Supplementary Figure 35. 
1
H and 
13
C NMR spectra of N
1
-(4-(tert-Butyl)phenyl)-N
6
-(1-(4-
fluorophenyl)-1H-indazol-5-yl)adipamide (3z)  
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Supplementary Figure 36. 
1
H and 
13
C NMR spectra of N-(2,5-
Dimethoxyphenyl)cyclobutanecarboxamide (4a) 
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Supplementary Figure 37. 
1
H and 
13
C NMR spectra of N-(Naphthalen-1-
yl)cyclopentanecarboxamide (4b) 
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Supplementary Figure 38. 
1
H and 
13
C NMR spectra of tert-Butyl 3-((4-(tert-
butyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate (4c) 
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Supplementary Figure 39. 
1
H and 
13
C NMR spectra of N-(9H-Fluoren-2-
yl)cyclohexanecarboxamide (4d) 
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Supplementary Figure 40. 
1
H and 
13
C NMR spectra of N-(3-Fluoro-4-methylphenyl)tetrahydro-
2H-pyran-4-carboxamide (4e) 
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Supplementary Figure 41. 
1
H and 
13
C NMR spectra of N-([1,1'-Biphenyl]-3-yl)-1-
methylcyclopropane-1-carboxamide (4f) 
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Supplementary Figure 42. 
1
H and 
13
C NMR spectra of N-(4-(tert-butyl)phenyl)pivalamide (4g) 
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Supplementary Figure 43. 
1
H and 
13
C NMR spectra of N-(4-(tert-butyl)phenyl)adamantane-1-
carboxamide (4h) 
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Supplementary Figure 44. 
1
H and 
13
C NMR spectra of N-(4-(tert-butyl)phenyl)tetradecanamide 
(4i) 
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Supplementary Figure 45. 
1
H and 
13
C NMR spectra of N-(4-((4-
Methoxyphenyl)amino)phenyl)benzamide (5a) 
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Supplementary Figure 46. 
1
H and 
13
C NMR spectra of N-(3-Methoxy-4-methylphenyl)benzamide 
(5b)  
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Supplementary Figure 47. 
1
H and 
13
C NMR spectra of 4-(Dimethylamino)-N-(p-tolyl)benzamide 
(5c)  
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Supplementary Figure 48. 
1
H and 
13
C NMR spectra of 4-Amino-N-(4-(tert-
butyl)phenyl)benzamide (5d) 
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Supplementary Figure 49. 
1
H and 
13
C NMR spectra of N-(2,3-Dihydro-1H-inden-4-yl)-4-
methoxybenzamide (5e) 
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Supplementary Figure 50. 
1
H and 
13
C NMR spectra of 4-(tert-Butyl)-N-(3-
(methylthio)phenyl)benzamide (5f) 
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Supplementary Figure 51. 
1
H and 
13
C NMR spectra of 4-(tert-Butyl)-N-(3-cyano-4-
methylphenyl)benzamide (5g) 
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Supplementary Figure 52. 
1
H and 
13
C NMR spectra of 4-(tert-Butyl)-N-(4-
(methylsulfonyl)phenyl)benzamide (5h) 
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Supplementary Figure 53. 
1
H and 
13
C NMR spectra of 4-(tert-Butyl)-N-(4-(2-((tert-
butyldimethylsilyl)oxy)ethyl)phenyl)benzamide (5i) 
 S-54   
 
Supplementary Figure 54. 
1
H and 
13
C NMR spectra of N-(4-(9H-Carbazol-9-yl)phenyl)-4-
methylbenzamide (5j) 
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Supplementary Figure 55. 
1
H and 
13
C NMR spectra of N-(4-(tert-Butyl)phenyl)-4-
fluorobenzamide (5k) 
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Supplementary Figure 56. 
1
H and 
13
C NMR spectra of N-(4-(tert-Butyl)phenyl)-4-
(trifluoromethyl)benzamide (5l) 
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Supplementary Figure 57. 
1
H and 
13
C NMR spectra of N-(2,4-Dimethylphenyl)-3-
methoxybenzamide (5m) 
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Supplementary Figure 58. 
1
H and 
13
C NMR spectra of N-(3-(Trifluoromethyl)phenyl)-2-
naphthamide (5n) 
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Supplementary Figure 59. 
1
H and 
13
C NMR spectra of N-(p-Tolyl)cinnamamide (5o) 
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Supplementary Figure 60. 
1
H and 
13
C NMR spectra of 5-Methyl-N-(p-tolyl)nicotinamide (5p) 
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Supplementary Figure 61. 
1
H and 
13
C NMR spectra of N-(p-Tolyl)thiophene-3-carboxamide (5q)   
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Supplementary Figure 62. 
1
H and 
13
C NMR spectra of N-(p-Tolyl)furan-3-carboxamide (5r) 
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Supplementary Figure 63. 
1
H and 
13
C NMR spectra of 1-Benzyl-N-(4-(tert-butyl)phenyl)-1H-
indole-6-carboxamide (5s) 
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Supplementary Figure 64. 
1
H and 
13
C NMR spectra of 8-Methoxydibenzo[b,f][1,4]thiazepin-
11(10H)-one (5t) 
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Supplementary Figure 65. 
1
H and 
13
C NMR spectra of Dibenzo[b,f][1,4]oxazepin-11(10H)-one 
(5u)  
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Supplementary Figure 66. 
1
H and 
13
C NMR spectra of 7-Chlorodibenzo[b,f][1,4]oxazepin-
11(10H)-one (5v) 
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Supplementary Figure 67. 
1
H and 
13
C NMR spectra of 8-Chlorodibenzo[b,f][1,4]thiazepin-
11(10H)-one (6a) 
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Supplementary Figure 68. 
1
H and 
13
C NMR spectra of Dibenzo[b,f][1,4]thiazepin-11(10H)-one 
(6b) 
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Supplementary Figure 69. 
1
H and 
13
C NMR spectra of 2-(2-Chlorophenyl)-N-(2-
phenylbenzo[d]oxazol-5-yl)acetamide (6c) 
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Supplementary Figure 70. 
1
H and 
13
C NMR spectra of N-(2-Phenylbenzo[d]oxazol-5-
yl)benzamide (6d) 
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Supplementary Figure 71. 
1
H and 
13
C NMR spectra of N-(2-(4-Fluorophenyl)benzo[d]oxazol-5-
yl)-2-phenylacetamide (6e) 
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Supplementary Figure 72. 
1
H and 
13
C NMR spectra of (R)-3a-Ethyl-2,3,3a,4,5,7-
hexahydrobenzo[2,3]azonino[6,5,4-hi]indolizin-6(1H)-one ((-)-Rhazinilam, 6f)  
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Supplementary Figure 73. 
1
H and 
13
C NMR spectra of N-(4-(tert-Butyl)phenyl)-6-((4,4-
dimethylthiochroman-6-yl)ethynyl)nicotinamide (6g)  
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Supplementary Figure 74. 
1
H and 
13
C NMR spectra of N-(4-(tert-Butyl)phenyl)-2-(4-chloro-2-
methylphenoxy)acetamide (6h) 
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Supplementary Tables 
 
 
Supplementary Table 1. Optimization of Ligand in Nickel-Catalyzed Reductive Coupling of Methyl 
Benzoate with Nitrobenzene.  
 
 
 
Supplementary Table 2. Optimization of Loading of Nitrobenzene in Nickel-Catalyzed Reductive 
Coupling of Methyl Benzoate with Nitrobenzene.  
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Supplementary Table 3. Optimization of Loadings of Zinc and Chlorotrimethylsilane in Nickel-
Catalyzed Reductive Coupling of Methyl Benzoate with Nitrobenzene.  
 
 
 
 
 
 
Supplementary Table 4. Optimization of Loadings of Ni(glyme)Cl2 and 1,10-phenanthroline in 
Nickel-Catalyzed Reductive Coupling of Methyl Benzoate with Nitrobenzene.  
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Supplementary Table 5. Optimization of temperature in Nickel-Catalyzed Reductive Coupling of 
Methyl Benzoate with Nitrobenzene.  
 
 
 
 
 
 
Supplementary Table 6. Optimization of Solvent in Nickel-Catalyzed Reductive Coupling of Methyl 
Benzoate with Nitrobenzene  
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Supplementary Table 7. Optimization of Reductant in Nickel-Catalyzed Reductive Coupling of 
Methyl Benzoate with Nitrobenzene.  
 
 
 
 
 
 
Supplementary Table 8. Optimization of Halotrimethylsilane Additive in Nickel-Catalyzed Reductive 
Coupling of Methyl Benzoate with Nitrobenzene.  
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Supplementary Table 9. Optimization of Transition Metal Catalyst in Nickel-Catalyzed Reductive 
Coupling of Methyl Benzoate with Nitrobenzene.  
 
 
 
Supplementary Table 10. Control Experiments in Nickel-Catalyzed Reductive Coupling of Methyl 
Benzoate with Nitrobenzene.  
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Supplementary Table 11. Optimizations of Nickel-Catalyzed Reductive Coupling of Methyl 
Decanoate with Nitrobenzene.  
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Supplementary Table 12. Optimization of Zn and TMSCl loading for the reaction between 
nitrosobenzene and methyl decanoate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 13. Optimizaion of Zn and TMSCl loading for the reaction between N-
phenylhydroxyamine and methyl decanoate. 
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Supplementary Table 14. Screening of conditions for the reaction between aniline and methyl 
decanoate. 
 
  
Supplementary Table 15. Optimizaion of Zn and TMSCl loading for the reaction between 
azoxybenzene and methyl decanoate 
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Supplementary Methods 
 
 
(A) General Analytical Information. 
  Nuclear Magnetic Resonance spectra were recorded on a Bruker Avance 400 MHz instruments at 
ambient temperature. All 
1
H NMR spectra were measured in part per million (ppm) relative to the 
signal of tetramethylsilane (TMS) added into the deuterated chloroform (CDCl3, 0.00 ppm), the signal 
of residual dichloromethane in deuterated dichloromethane (CD2Cl2, 5.32 ppm), or the signal of 
residual dimethyl sulfoxide in deuterated dimethyl sulfoxide (DMSO-d6, 2.50 ppm).
1
 Data for 
1
H NMR 
were reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qu 
= quintet, m = multiplet, ovrlp = overlap, br = broad), coupling constants, and integration. All 
13
C NMR 
spectra were reported in ppm relative to CDCl3 (77.16 ppm), CD2Cl2 (53.84 ppm), or DMSO-d6 (39.52 
ppm)
1
 and were obtained with complete 
1
H decoupling. The 
19
F NMR spectra were obtained with 
complete 
1
H decoupling as well. ,,-Trifluorotoluene was used as the internal standard, with a 
chemical shift of -63.73 ppm relative to CFCl3. All GC analyses were performed on a Perkin-Elmer 
Clarus 400 GC system with a FID detector. All GC-MS analyses were performed on an Agilent 
Technologies 7890A GC system equipped with a 5975C MS detector. High-resolution mass spectra 
(HRMS) by electrospray ionization (ESI) method were performed at the EPFL ISIC Mass Spectroscopy 
Service with a Micro Mass QTOF Ultima spectrometer.  
 
 
(B) General Reagent Information. 
  Unless otherwise noted, all chemicals were used as received without further purifications. Anhydrous 
N-methylpyrrolidone (NMP) (99.8% purity, in Sure-Seal bottle), zinc powder (Zn, >98% purity), 
manganese powder (Mn, 99.99% purity), chlorotrimethylsilane (TMSCl, ≥98% purity), and nickel(II) 
chloride ethylene glycol dimethyl ether complex (Ni(glyme)Cl2) were purchased from Aldrich 
Chemical Co.. 1,10-Phenanthroline (phen, ≥99% purity) was purchased from Acros Chemicals. 
Iodotrimethylsilane (TMSI, ≥95% purity) was purchased from TCI Chemicals. The following known 
starting materials (esters and nitroarenes) were prepared according to the literature procedures:
2-16  
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(C) General Manipulation Considerations.    
   
  All manipulations for the nickel-catalyzed reductive coupling reactions of nitroarenes with esters 
were set up in a 30 mL Teflon-screw capped test tubes (unless otherwise noted) under an inert nitrogen 
(N2) atmosphere using glove-box techniques. The test tubes were then sealed with airtight electrical 
tapes and the reaction mixtures were stirred in a preheated oil-bath. Flash column chromatography was 
performed using silica gel (Silicycle, ultra pure grade). Preparative thin-layer chromatography 
(preparative TLC) was performed using preparative TLC plate (Merck  Millipore, TLC Silica gel 60 
F254, 20 x 20 cm, catalogue number: 1.05715.0001) in a developing tank. Notably, the TLC plates used 
for the purification of amide products were washed with hexanes/triethylamine solution (volume ratio 
~20:1) prior to the use in order to minimize the product loss. The eluents for column chromatography 
and preparative TLC were presented as ratios of solvent volumes. Yields reported in the publication 
are of isolated materials unless otherwise noted. All new starting materials and all amide products 
were characterized by 
1
H and 
13
C NMR spectroscopies and high-resolution mass spectrometry 
(HRMS).  
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Synthesis of Starting Materials:  
 
 
 
 
Methyl 5-(4-Chloro-3,5-dimethylphenoxy)pentanoate (S1). An oven-dried 100 mL round-bottom 
flask equipped with a Teflon-coated magnetic stir bar was sequentially charged with 4-chloro-3,5-
dimethylphenol (1 equiv, 1.81 g, 11.6 mmol), DMF (anhydrous, 30 mL), and sodium hydride (60% in 
paraffin oil, 1.5 equiv, 696 mg, 17.4 mmol). The resulting mixture was stirred at room temperature for 
30 min. Sodium iodide (40 mol %, 697 mg, 4.64 mmol) and methyl 5-chloropentanoate (1 equiv, 1.67 
mL, 11.6 mmol) were then added, and the reaction mixture was stirred at 90 
o
C in a preheated oil bath 
overnight. After the reaction, the crude product was quenched with water (~20 mL) and then washed 
with saturated NaOH solution (~200 mL) and EtOAc (~100 mL). The organic fraction was 
concentrated in vacuo with the aid of a rotary evaporator, and the residue was purified by flash 
chromatography with silica gel (without prior washing with Et3N/hexanes) using a mixture of 
hexanes/EtOAc (5:1) as an eluent to afford the title compound (S1) as yellow oil (1.72 g, 55%). 
1
H 
NMR (400 MHz, CDCl3): δ 6.61 (s, 2 H), 3.90 (t, J = 6.0 Hz, 2 H), 3.66 (s, 3 H), 2.38 (t, J = 7.1 Hz, 2 
H), 2.32 (s, 6 H), 1.81-1.76 (ovrlp, 4 H). 
13
C NMR (100 MHz, CDCl3): δ 173.8, 156.8, 137.0, 126.1, 
114.5, 67.5, 51.5, 33.7, 28.7, 21.7, 20.9. HRMS (ESI): Calcd for C14H20ClO3 [M+H]: 271.1095; 
Found: 271.1097.  
 
 
 
 
Methyl 5-Morpholinopentanoate (S2).  An oven-dried 100 mL round-bottom flask equipped with a 
Teflon-coated magnetic stir bar was sequentially charged with morpholine (5 equiv, 8.6 mL, 99.5 
mmol), methyl 5-chloropentanoate (1 equiv, 3.00 g, 19.9 mmol), sodium iodide (1 equiv, 1.50 g, 9.95 
mmol), and DMF (anhydrous, 30 mL), and the reaction mixture was stirred at 90 
o
C in a preheated oil 
bath overnight. After the reaction, the crude product was washed with water (~300 mL) and EtOAc 
(~100 mL). The organic fraction was concentrated in vacuo with the aid of a rotary evaporator, and the 
residue was purified by flash chromatography with silica gel (without prior washing with 
Et3N/hexanes) using a mixture of hexanes/EtOAc (3:1) as an eluent to afford the title compound (S2) 
as brown oil (1.23 g, 31%). 
1
H NMR (400 MHz, CDCl3): δ 3.71 (t, J = 4.7 Hz, 4 H), 3.67 (s, 3 H), 
2.42 (t, J = 4.2 Hz, 4 H), 2.36-2.32 (ovrlp, 4 H), 1.66 (qu, J = 7.8 Hz, 2 H), 1.52 (qu, J = 7.9 Hz, 2 H). 
13
C NMR (100 MHz, CDCl3): δ 174.1, 67.1, 58.6, 53.8, 51.6, 34.0, 26.1, 22.9. HRMS (ESI): Calcd 
for C10H20NO3 [M+H]: 202.1443; Found: 202.1448.  
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Methyl 6-Morpholino-6-oxohexanoate (S3). An oven-dried 250 mL round-bottom flask equipped 
with a Teflon-coated magnetic stir bar was sequentially charged with morpholine (1.2 equiv, 1.1 mL, 
12.8 mmol), CH2Cl2 (100 mL), triethylamine (1.8 equiv, 2.7 mL, 19.3 mmol), N,N-dimethyl-4-
aminopyridine (3 mol %, 0.321 mmol, 39 mg), and methyl 6-chloro-6-oxohexanoate (1 equiv, 1.91 g, 
10.7 mmol), and the resulting mixture was stirred at room temperature overnight. After the reaction, 
the crude product was washed with dilute HCl solution (~1 M, ~100 mL). The aqueous fraction was 
removed, and the organic fraction was further neutralized with saturated NaHCO3 solution (~100 mL). 
The organic fraction was concentrated in vacuo with the aid of a rotary evaporator, and the residue 
was purified by flash chromatography with silica gel (without prior washing with Et3N/hexanes) using 
a mixture of hexanes/EtOAc (3:1) as an eluent to afford the title compound (S3) as brown oil (1.10 g, 
45%). 
1
H NMR (400 MHz, CDCl3): δ 3.68-3.65 (ovrlp, 7 H), 3.61 (t, J = 4.7 Hz, 2 H), 3.46 (t, J = 4.8 
Hz, 2 H), 2.37-2.31 (ovrlp, 4 H), 1.72-1.65 (ovrlp, 4 H). 
13
C NMR (100 MHz, CDCl3): δ 173.8, 171.1, 
66.9, 66.6, 51.5, 45.9, 41.8, 33.7, 32.6, 24.6, 24.5. HRMS (ESI): Calcd for C11H20NO4 [M+H]: 
230.1387; Found: 230.1391.  
 
 
 
 
Methyl 6-(Cyclohexylamino)-6-oxohexanoate (S4). An oven-dried 250 mL round-bottom flask 
equipped with a Teflon-coated magnetic stir bar was sequentially charged with cyclohexylamine (2.5 
equiv, 2.9 mL, 25.0 mmol), CH2Cl2 (100 mL), and methyl 6-chloro-6-oxohexanoate (1 equiv, 1.79 g, 
10.0 mmol), and the resulting mixture was stirred at room temperature overnight. After the reaction, 
the crude product was washed with diluted HCl solution (~1 M, ~100 mL). The aqueous fraction was 
removed, and the organic fraction was further neutralized with saturated NaHCO3 solution (~100 mL). 
The organic fraction was concentrated in vacuo with the aid of a rotary evaporator, and the residue 
was purified by recrystallized using CH2Cl2/hexanes as solvents to afford the title compound (S4) as 
white solid (1.93 g, 80%). 
1
H NMR (400 MHz, CDCl3): δ 5.75 (s, 1 H), 3.80-3.71 (m, 1 H), 3.67 (s, 3 
H), 2.34 (t, J = 6.6 Hz, 2 H), 2.17 (t, J = 6.6 Hz, 2 H), 1.90 (dd, J = 11.4 Hz, J = 2.5 Hz, 2 H), 1.74-
1.59 (ovrlp, 7 H), 1.36 (qt, J = 12.2 Hz, J  = 3.2 Hz, 2 H), 1.14 (qu/d, J = 12.2 Hz, J = 3.4 Hz, 2 H). 
13
C NMR (100 MHz, CDCl3): δ 174.0, 171.6, 51.5, 48.1, 36.4, 33.7, 33.2, 25.6, 25.2, 24.9, 24.4. 
HRMS (ESI): Calcd for C13H24NO3 [M+H]: 242.1756; Found: 242.1758.  
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Methyl 6-((1-(4-Fluorophenyl)-1H-indazol-5-yl)amino)-6-oxohexanoate (S5). An oven-dried 250 
mL round-bottom flask equipped with a Teflon-coated magnetic stir bar was sequentially charged with 
1-(4-fluorophenyl)-1H-indazol-5-amine
17
 (1 equiv, 327 mg, 1.44 mmol), CH2Cl2 (30 mL), 
triethylamine (1.5 equiv, 0.3 mL, 2.16 mmol), N,N-dimethyl-4-aminopyridine (10 mol %, 18 mg, 
0.144 mmol), and methyl 6-chloro-6-oxohexanoate (1.1 equiv, 283 mg, 1.58 mmol), and the resulting 
mixture was stirred at room temperature overnight. After the reaction, the crude product was washed 
with dilute HCl solution (~1 M, ~30 mL). The aqueous fraction was removed, and the organic fraction 
was further neutralized with saturated NaHCO3 solution (~50 mL). The organic fraction was 
concentrated in vacuo with the aid of a rotary evaporator, and the residue was purified by 
recrystallization using CH2Cl2/hexanes as solvents to afford the title compound (S5) as white solid 
(500 mg, 94%). 
1
H NMR (400 MHz, CDCl3): δ 8.14-8.11 (ovrlp, 2 H), 7.68-7.58 (ovrlp, 3 H), 7.59 (d, 
J = 9.0 Hz, 1 H), 7.43 (dd, J = 9.0 Hz, J = 1.8 Hz, 1 H), 7.22 (dd, 
3
JHH = 8.5 Hz, 
3
JHH = 8.5 Hz, 1 H), 
3.69 (s, 3 H), 2.45-2.38 (ovrlp, 4 H), 1.85-1.66 (ovrlp, 4 H). 
13
C NMR (100 MHz, CDCl3 ): δ 174.3, 
171.1, 161.3 (d, 
1
JCF = 245.0 Hz), 136.3, 135.5, 132.2, 125.5, 124.5 (d, 
3
JCF = 8.4 Hz), 121.9, 116.5 (d, 
2
JCF = 22.8 Hz), 112.2, 110.5, 51.8, 37.2, 33.7, 25.1, 24.4. HRMS (ESI): Calcd for C20H21FN3O3 
[M+H]: 370.1567; Found: 370.1564.  
 
 
 
 
Pentyl 2-((4-Methoxy-2-nitrophenyl)thio)benzoate (S6). The title compound was synthesized 
according to the literature procedures with small variations.
18
 In a nitrogen-filled glove box, an 30 mL 
Teflon-screw cap test tube equipped with a Teflon-coated magnetic stir bar was sequentially charged 
with 1-bromo-4-methoxy-2-nitrobenzene (1 equiv, 232 mg, 1.00 mmol), 2-mercaptobenzoic acid (1.2 
equiv, 190 mg, 1.20 mmol), K2CO3 (1.5 equiv, 207 mg, 1.50 mmol), copper powder (20 mol %, 13 
mg), and 1-pentanol (3 mL), and the resulting mixture was stirred at 140 
o
C in a preheated oil bath for 
24 h. After the reaction, the crude product was washed with EtOAc (~100 mL) and saturated NaOH 
solution (~100 mL). The aqueous fraction was removed, and the organic fraction was further washed 
with water (~100 mL). The organic fraction was concentrated in vacuo with the aid of a rotary 
evaporator, and the residue was purified by flash chromatography with silica gel (without prior 
washing with Et3N/hexanes) using a mixture of hexanes/EtOAc (4:1) as an eluent to afford the title 
compound (S6) as brown oil (296 mg, 75%). 
1
H NMR (400 MHz, CDCl3): δ 7.94 (dd, J = 7.5 Hz, J = 
1.0 Hz, 1 H), 7.55 (d, J = 2.6 Hz, 1 H), 7.39 (td, J = 7.4 Hz, J = 1.1 Hz, 1 H), 7.34 (d, J = 7.3 Hz, 1 H), 
7.21 (d, J = 8.8 Hz, 1 H), 7.16 (d, J = 7.4 Hz, 1 H), 7.05 (dd, J = 8.8 Hz, J = 2.6 Hz, 1 H), 4.27 (t, J = 
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6.6 Hz, 2 H), 3.88 (s, 3 H), 1.68 (qu, J = 6.8 Hz, 2 H), 1.40-1.28 (ovrlp, 4 H), 0.90 (t, J = 6.8 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 166.8, 159.3, 150.5, 137.2, 135.4, 132.43, 132.41, 132.1, 131.0, 
127.3, 123.7, 120.6, 109.5, 65.8, 56.1, 28.4, 28.3, 22.4, 14.1.  HRMS (ESI): Calcd for C19H22NO5S 
[M+H]: 376.1213; Found: 376.1221.   
 
 
 
---------------------------------------------------------------------------------------------------------------------------- 
 
 
 
Synthesis of Amides 
 
Nickel-Catalyzed Reductive Coupling of Nitroarene with Alkyl Alkanoate (General Procedure 
A). An oven-dried 30 mL re-sealable screw-cap test tube equipped with a Teflon-coated magnetic stir 
bar was sequentially charged with zinc powder (Zn, 4 equiv, 2.0 mmol, 131 mg), ester (1 equiv, 0.50 
mmol), nitroarene (1.2 equiv, 0.60 mmol), 1,10-phenanthroline (phen, 7.5 mol %, 6.8 mg), nickel(II) 
chloride ethylene glycol dimethyl ether complex (Ni(glyme)Cl2, 7.5 mol %, 8.3 mg), N-
methylpyrrolidone solvent (NMP, 1.0 mL), and chlorotrimethylsilane (TMSCl, 2 equiv, 1.0 mmol, 128 
μL). The resulting mixture was stirred at 90 oC in a preheated oil bath for 16 h. After the reaction, the 
reaction mixture was cooled down to room temperature, and the crude product was acidified with 
saturated NH4Cl solution (~5 mL) and then neutralized with saturated NaHCO3 solution (~10 mL). The 
crude product in the aqueous fraction was extracted with EtOAc (~20 mL). The aqueous fraction was 
further washed with EtOAc (3 x ~10 mL). The combined organic fractions were concentrated in vacuo 
with the aid of a rotary evaporator. The crude product residue was purified by preparative thin-layer 
chromatography (TLC) using a solvent mixture (dichloromethane (CH2Cl2), hexanes, and/or ethyl 
acetate (EtOAc)) as an eluent to afford the purified amide product.  
 
 
Nickel-Catalyzed Reductive Coupling of Nitroarene with Alkyl Arenoate (General Procedure B). 
An oven-dried 30 mL re-sealable screw-cap test tube equipped with a Teflon-coated magnetic stir bar 
was sequentially charged with zinc powder (Zn, 4 equiv, 2.0 mmol, 131 mg), ester (1 equiv, 0.50 
mmol), nitroarene (1.3 equiv, 0.65 mmol), 1,10-phenanthroline (phen, 7.5 mol %, 6.8 mg), nickel(II) 
chloride ethylene glycol dimethyl ether complex (Ni(glyme)Cl2, 7.5 mol %, 8.3 mg), N-
methylpyrrolidone solvent (NMP, 1.0 mL), and chlorotrimethylsilane (TMSCl, 2 equiv, 1.0 mmol, 128 
μL). The resulting mixture was stirred at 120 oC in a preheated oil bath for 16 h. After the reaction, the 
reaction mixture was cooled down to room temperature, and the crude product was acidified with 
saturated NH4Cl solution (~5 mL) and then neutralized with saturated NaHCO3 solution (~10 mL). The 
crude product in the aqueous fraction was extracted with EtOAc (~20 mL). The aqueous fraction was 
further washed with EtOAc (3 x ~10 mL). The combined organic fractions were concentrated in vacuo 
with the aid of a rotary evaporator. The crude product residue was purified by preparative thin-layer 
chromatography (TLC) using a solvent mixture (dichloromethane (CH2Cl2), hexanes, and/or ethyl 
acetate (EtOAc)) as an eluent to afford the purified amide product.  
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N-(4-(tert-Butyl)phenyl)decanamide (3a).  
 
  (i) Synthesized from methyl decanoate: Following the general procedure A, the title compound was 
prepared using methyl decanoate (0.50 mmol, 93 mg) and 1-(tert-butyl)-4-nitrobenzene (0.60 mmol, 
108 mg). The crude product was purified by preparative TLC using hexanes/CH2Cl2 (5:1) as an eluent 
to afford the title compound (3a) as pale brown solid (110 mg, 72%). 
1
H NMR (400 MHz, CDCl3): δ 
7.43 (d, J = 8.5 Hz, 2 H), 7.32 (d, J = 8.5 Hz, 2 H), 7.27 (s, 1 H), 2.33 (t, J = 7.6 Hz, 2 H), 1.72 (qu, J 
= 7.3 Hz, 2 H), 1.39-1.22 (ovrlp, 21 H), 0.88 (t, J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 
171.5, 147.2, 135.5, 125.9, 119.8, 37.9, 34.5, 32.0, 31.5, 29.6, 29.5, 29.4, 25.9, 22.8, 14.2. HRMS 
(ESI): Calcd for C20H34NO [M+H]: 304.2640; Found: 304.2646.   
 
  (ii) Synthesized from tert-butyl decanoate: Following the general procedure A, the title compound 
was prepared using tert-butyl decanoate (0.50 mmol, 114 mg), 1-(tert-butyl)-4-nit1robenzene (0.75 
mmol, 134 mg), manganese (Mn, 5 equiv, 138 mg), iodotrimethylsilane (TMSI, 2 equiv, 143 μL), 
Ni(glyme)Cl2 (15 mol %, 16.5 mg), and phen (15 mol %, 13.5 mg) at the reaction temperature of 140 
o
C. The crude product was purified by preparative TLC using hexanes/EtOAc (8:1) as an eluent to 
afford the title compound (3a) as pale brown solid (96 mg, 63%). Spectral and analytical data were 
identical to those reported for the same compound above.  
 
 
 
 
N-(4-Methoxyphenyl)decanamide (3b). Following the general procedure A, the title compound was 
prepared using methyl decanoate (0.50 mmol, 93 mg) and 1-methoxy-4-nitrobenzene (0.60 mmol, 92 
mg). The crude product was purified by preparative TLC using hexanes/CH2Cl2 (3:1) as an eluent to 
afford the title compound (3b) as pale brown solid (95 mg, 68%). 
1
H NMR (400 MHz, CDCl3): δ 7.41 
(d, J = 8.8 Hz, 2 H), 7.15 (s, 1 H), 6.84 (d, J = 8.7 Hz, 2 H), 3.78 (s, 3 H), 2.32 (t, J = 7.6 Hz, 2 H), 
1.71 (qu, J = 7.3 Hz, 2 H), 1.39-1.21 (ovrlp, 12 H), 0.88 (t, J = 6.9 Hz, 3 H). 
13
C NMR (100 MHz, 
CDCl3): δ 171.4, 156.5, 131.2, 121.9, 114.2, 55.6, 37.8, 32.0, 29.6, 29.5, 29.45, 29.42, 25.9, 22.8, 14.2. 
HRMS (ESI): Calcd for C17H28NO2 [M+H]: 278.2120; Found: 278.2126.   
 
 
 
 
N-(4-(Methylthio)phenyl)decanamide (3c). Following the general procedure A, the title compound 
was prepared using methyl decanoate (0.5 mmol, 93 mg) and methyl(4-nitrophenyl)sulfane (0.60 
mmol, 102 mg). The crude product was purified by preparative TLC using hexanes/CH2Cl2 (4:1) as an 
eluent to afford the title compound (3c) as brown solid (98 mg, 67%). 
1
H NMR (400 MHz, CDCl3): δ 
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7.45 (d, J = 8.4 Hz, 2 H), 7.23 (d, J = 8.6 Hz, 2 H), 7.12 (s, 1 H), 2.46 (s, 3 H), 2.34 (t, J = 7.6 Hz, 2 
H), 1.72 (qu, J = 7.3 Hz, 2 H), 1.38-1.23 (ovrlp, 12 H), 0.88 (d, J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, 
CDCl3): δ 171.4, 135.8, 133.5, 128.2, 120.5, 38.0, 32.0, 29.6, 29.5, 29.4, 25.8, 22.8, 16.9, 14.3. HRMS 
(ESI): Calcd for C17H28NOS [M+H]: 294.1891; Found: 294.1892.  
 
 
 
 
N-(3-Bromo-4-methylphenyl)decanamide (3d). Following the general procedure A, the title 
compound was prepared using methyl decanoate (1 equiv, 0.50 mmol, 93 mg) and 2-bromo-1-methyl-
4-nitrobenzene (1.5 equiv, 0.75 mmol, 163 mg). The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (3d) as deep brown solid (130 
mg, 68%). 
1
H NMR (400 MHz, CDCl3): δ 7.76 (s, 1 H), 7.45 (s, 1 H), 7.34 (d, J = 7.7 Hz, 1 H), 7.13 
(d, J = 8.2 Hz, 1 H), 2.36-2.29 (ovrlp, 5 H), 1.68 (qu, J = 7.3 Hz, 2 H), 1.36-1.21 (ovrlp, 12 H), 0.87 (t, 
J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 171.8, 136.9, 133.6, 130.8, 124.8, 123.7, 119.0, 
37.8, 32.0, 29.6, 29.5, 29.4, 25.7, 22.8, 22.4, 14.2. HRMS (ESI): Calcd for C17H27BrNO [M+H]: 
340.1278; Found: 340.1260.  
 
 
 
 
N-(3-Chloro-4-methoxyphenyl)palmitamide (3e). Following the general procedure A, the title 
compound was prepared using hexadecyl palmitate (1 equiv, 0.50 mmol, 240 mg), 2-chloro-1-
methoxy-4-nitrobenzene (1.5 equiv, 0.75 mmol, 141 mg), Ni(glyme)Cl2 (15 mol %, 16.5 mg) and phen 
(15 mol %, 13.5 mg). The crude product was purified by preparative TLC using hexanes/CH2Cl2 (3:1) 
as an eluent to afford the title compound (3e) as brown solid (105 mg, 53%). 
1
H NMR (400 MHz, 
CDCl3): δ 7.55 (d, J = 2.6 Hz, 1 H), 7.38 (dd, J = 8.8 Hz, J = 2.6 Hz, 1 H), 7.30 (s, 1 H), 6.85 (d, J = 
8.8 Hz, 1 H), 3.87 (s, 3 H), 2.32 (t, J = 7.6 Hz, 2 H), 1.70 (qu, J = 7.7 Hz, 2 H), 1.37-1.22 (ovrlp, 24 
H), 0.88 (t, J = 6.9 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 171.6, 151.9, 131.7, 122.64, 122.56, 
119.8, 112.3, 56.5, 37.7, 32.1, 29.84, 29.82, 29.80, 29.76, 29.6, 29.52, 29.50, 29.4, 25.8, 22.8, 14.3. 
HRMS (ESI): Calcd for C23H39ClNO2 [M+H]: 396.2669; Found: 396.2666.  
 
 
 
 
N-(4-(1H-Pyrrol-1-yl)phenyl)decanamide (3f). Following the general procedure A, the title 
compound was prepared using methyl decanoate (0.50 mmol, 93 mg) and 1-(4-nitrophenyl)-1H-
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pyrrole (0.60 mmol, 113 mg). The crude product was purified by preparative TLC using 
hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (3f) as brown solid (80 mg, 51%). 
1
H 
NMR (400 MHz, CDCl3): δ 7.57 (d, J = 8.3 Hz, 2 H), 7.38 (s, 1 H), 7.32 (d, J = 8.4 Hz, 2 H), 7.03 (s, 
2 H), 6.33 (s, 2 H), 2.36 (t, J = 7.6 Hz, 2 H), 1.73 (qu, J = 2 Hz, 2 H), 1.39-1.26 (ovrlp, 12 H), 0.88 (t, 
J = 7.1 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 171.7, 137.1, 135.8, 121.14, 121.07, 119.4, 110.4, 
37.9, 32.0, 29.6, 29.5, 29.43, 29.41, 25.8, 22.8, 14.2. HRMS (ESI): Calcd for C20H29N2O [M+H]: 
313.2286; Found: 313.2274.  
 
 
 
 
N-(4-(1H-Pyrazol-1-yl)phenyl)decanamide (3g). Following the general procedure A, the title 
compound was prepared using methyl decanoate (1 equiv, 0.50 mmol, 93 mg), 1-(4-nitrophenyl)-1H-
pyrazole (1.5 equiv, 0.75 mmol, 142 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), and phen (10 mol %, 
9.0 mg) under the reaction temperature of 120 
o
C. The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (4:1) as an eluent to afford the title compound (3g) as pale brown solid (78 mg, 
50%). 
1
H NMR (400 MHz, CDCl3): δ 7.88 (d, J = 2.4 Hz, 1 H), 7.71 (s, 1 H), 7.65-7.60 (ovrlp, 4 H), 
7.22 (s, 1 H), 6.46 (s, 1 H), 2.37 (t, J = 7.6 Hz, 2 H), 1.74 (qu, J = 7.6 Hz, 2 H), 1.43-1.22 (ovrlp, 12 
H), 0.88 (t, J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 171.5, 141.0, 136.6, 136.5, 126.8, 120.7, 
120.0, 107.7, 38.0, 32.0, 29.6, 29.5, 29.43, 29.42, 25.7, 22.8, 14.3. HRMS (ESI): Calcd for C19H28N3O 
[M+H]: 314.2237; Found: 314.2217.  
 
 
 
 
N-(Quinolin-6-yl)decanamide (3h). Following the general procedure A, the title compound was 
prepared using methyl decanoate (1 equiv, 0.50 mmol, 93 mg), 6-nitroquinoline (1.5 equiv, 0.75 
mmol, 131 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), and phen (10 mol %, 9.0 mg). The crude product 
was purified by preparative TLC using hexanes/CH2Cl2 (1:1) as an eluent to afford the title compound 
(3h) as pale brown solid (105 mg, 70%). 
1
H NMR (400 MHz, CDCl3): δ 8.81 (s, 1 H), 8.70 (s, 1 H), 
8.45 (s, 1 H), 8.05 (d, J = 8.4 Hz, 1 H), 7.98 (d, J = 9.0 Hz, 1 H), 7.61 (d, J = 9.1 Hz, 1 H), 7.34 (dd, J 
= 8.4 Hz, J = 4.3 Hz, 1 H), 2.42 (t, J = 7.6 Hz, 2 H), 1.74 (qu, J = 7.7 Hz, 2 H), 1.36-1.17 (ovrlp, 12 
H), 0.86 (t, J = 7.1 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 172.5, 149.2 145.4, 136.5, 136.1, 129.8, 
129.0, 123.5, 121.7, 116.2, 37.8, 31.9, 29.50, 29.47, 29.39, 29.3, 25.8, 22.7, 14.2. HRMS (ESI): Calcd 
for C19H27N2O [M+H]: 299.2128; Found: 299.2118.  
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N-(2-Methylbenzo[d]thiazol-6-yl)decanamide (3i). Following the general procedure A, the title 
compound was prepared using methyl decanoate (1 equiv, 0.50 mmol, 93 mg) and 2-methyl-6-
nitrobenzo[d]thiazole (1.5 equiv, 0.75 mmol, 146 mg), Ni(glyme)Cl2 (15 mol %, 16.5 mg), and phen 
(15 mol %, 13.5 mg) under the reaction temperature of 120 
o
C. The crude product was purified by 
preparative TLC using hexanes/CH2Cl2 (1:1) as an eluent to afford the title compound (3i) as deep 
brown solid (80 mg, 50%). 
1
H NMR (400 MHz, CDCl3): δ 8.43 (s, 1 H), 7.83 (d, J = 8.7 Hz, 1 H), 
7.39 (s, 1 H), 7.23 (dd, J = 8.7 Hz, J = 2.2 Hz, 1 H), 2.80 (s, 3 H), 2.38 (t, J = 7.6 Hz, 2 H), 1.74 (qu, J 
= 7.5 Hz, 2 H), 7.40-1.17 (ovrlp, 12 H), 0.88 (t, J = 6.9 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 
171.7, 166.6, 150.1, 136.8, 135.1, 122.4, 118.6, 112.5, 38.0, 32.0, 29.6, 29.5, 29.422, 29.415, 25.8, 
22.8, 20.2, 14.2. HRMS (ESI): Calcd for C18H27N2OS [M+H]: 319.1844; Found: 319.1842.  
 
 
 
 
N-(2-Phenylbenzo[d]oxazol-5-yl)decanamide (3j). Following the general procedure A, the title 
compound was prepared using methyl decanoate (0.50 mmol, 93 mg) and 5-nitro-2-
phenylbenzo[d]oxazole (0.60 mmol, 144 mg). The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (1:1) as an eluent to afford the title compound (3j) as deep brown solid (100 
mg, 55%). 
1
H NMR (400 MHz, CDCl3): δ 8.20 (d, J = 6.8 Hz, 2 H), 7.90 (s, 1 H), 7.77 (s, 1 H), 7.56-
7.45 (ovrlp, 5 H), 2.36 (t, J = 7.6 Hz, 2 H), 1.72 (qu, J = 7.5 Hz, 2 H), 1.36-1.24 (ovrlp, 12 H), 0.86 (d, 
J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 171.9, 163.9, 147.6, 142.5, 135.2, 131.7, 129.0, 
127.7, 127.1, 118.5, 111.7, 110.5, 37.8, 32.0, 29.6, 29.53, 29.46, 29.4, 25.8, 22.8, 14.2. HRMS (ESI): 
Calcd for C23H29N2O2 [M+H]: 365.2229; Found: 365.2227.  
 
 
 
 
 
N-(1-Methyl-1H-indol-5-yl)decanamide (3k). Following the general procedure A, the title compound 
was prepared using methyl decanoate (0.50 mmol, 93 mg) and 1-methyl-5-nitro-1H-indole (0.60 
mmol, 106 mg). The crude product was purified by preparative TLC using hexanes/CH2Cl2 (3:1) as an 
eluent to afford the title compound (3k) as pale brown solid (88 mg, 59%). 
1
H NMR (400 MHz, 
CDCl3): δ 7.81 (s, 1 H), 7.28-7.24 (ovrlp, 2 H), 7.21 (s, 1 H), 7.03 (d, J = 3.1 Hz, 1 H), 6.42 (d, J = 3.1 
Hz, 1 H), 3.76 (s, 3 H), 2.35 (t, J = 7.6 Hz, 2 H), 1.74 (qu, J = 7.6 Hz, 2 H), 1.39-1.19 (ovrlp, 12 H), 
0.88 (t, J = 7.0 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 171.5, 134.3, 130.3, 129.7, 128.6, 116.0, 
112.9, 109.4, 101.1, 38.0, 33.1, 32.0, 29.62. 29.57, 29.5, 29.4, 26.0, 22.8, 14.3. HRMS (ESI): Calcd 
for C19H29N2O [M+H]: 301.2280; Found: 301.2285.  
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N-(Dibenzo[b,d]thiophen-3-yl)decanamide (3l). Following the general procedure A, the title 
compound was prepared using methyl decanoate (0.50 mmol, 93 mg) and 3-
nitrodibenzo[b,d]thiophene (0.60 mmol, 149 mg). The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (4:1) as an eluent to afford the title compound (3l) as off-white solid (140 mg, 
79%). 
1
H NMR (400 MHz, CDCl3): δ 8.47 (s, 1 H), 8.00 (d, J = 7.7 Hz, 1 H), 7.81-7.76 (ovrlp, 2 H), 
7.66 (d, J = 8.5 Hz, 1 H), 7.42-7.32 (ovrlp, 3 H), 2.37 (t, J = 7.7 Hz, 2 H), 1.73 (qu, J = 7.0 Hz, 2 H), 
1.36-1.19 (ovrlp, 12 H), 0.87 (t, J = 6.2 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 172.1, 140.2, 136.2, 
135.4, 135.2, 134.9, 126.9, 124.4, 122.95, 122.85, 121.9, 119.8, 113.2, 37.9, 32.0, 29.59, 29.55, 29.5, 
29.4, 25.8, 22.8, 14.2.  HRMS (ESI): Calcd for C22H28NOS [M+H]: 354.1900; Found: 354.1885.  
 
 
 
 
(E)-3-Phenyl-N-(4-styrylphenyl)propanamide (3m). Following the general procedure A, the title 
compound was prepared using methyl 3-phenylpropanoate (0.50 mmol, 82 mg) and (E)-1-nitro-4-
styrylbenzene (0.60 mmol, 135 mg). The crude product was purified by preparative TLC using 
hexanes/CH2Cl2 (3:1) as an eluent to afford the title compound (3m) as pale brown solid (125 mg, 
76%). 
1
H NMR (400 MHz, DMSO-d6): δ 10.00 (s, 1 H), 7.62-7.52 (ovrlp, 6 H), 7.36 (t, J = 7.6 Hz, 2 
H), 7.31-7.23 (ovrlp, 5 H), 7.21-7.12 (ovrlp, 3 H), 2.92 (t, J = 7.8 Hz, 2 H), 2.64 (t, J = 7.6 Hz, 2 H). 
13
C NMR (100 MHz, DMSO-d6): δ 170.4, 141.2, 138.8, 137.2, 131.9, 128.7, 128.34, 128.26, 128.04, 
127.4, 126.93, 126.90, 126.3, 126.0, 119.1, 38.0, 30.8. HRMS (ESI): Calcd for C23H22NO [M+H]: 
328.1710; Found: 328.1686.  
 
 
 
 
N-(Benzo[d][1,3]dioxol-5-yl)undec-10-enamide (3n). Following the general procedure A, the title 
compound was prepared using methyl undec-10-enoate (0.50 mmol, 106 mg) and 5-
nitrobenzo[d][1,3]dioxole (0.60 mmol, 100 mg). The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (3:1) as an eluent to afford the title compound (3n) as brown solid (91 mg, 
60%). 
1
H NMR (400 MHz, CDCl3): δ 7.57 (s, 1 H), 7.21 (s, 1 H), 6.79 (d, J = 8.4 Hz, 1 H), 6.70 (d, J 
 S-95   
= 8.3 Hz, 1 H), 5.92 (2 H), 5.85-5.75 (m, 1 H), 5.01-4.91 (ovrlp, 2 H), 2.30 (t, J = 7.6 Hz, 2 H), 2.03 
(q, J = 7.2 Hz, 2 H), 1.69 (qu, J = 7.6 Hz, 2 H), 1.38-1.24 (ovrlp, 10 H). 
13
C NMR (100 MHz, CDCl3): 
δ 171.8, 147.7, 144.2, 139.2, 132.4, 114.2, 113.4, 108.0, 103.1, 101.2, 37.6, 33.8, 29.42. 29.41, 29.36, 
29.2, 29.0, 25.8. HRMS (ESI): Calcd for C18H26NO3 [M+H]: 304.1913; Found: 304.1913. 
 
 
 
 
N-Phenyloleamide (3o). Following the general procedure A, the title compound was prepared using 
methyl oleate (0.50 mmol, 148 mg) and nitrobenzene (0.60 mmol, 62 μL). The crude product was 
purified by preparative TLC using hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (3o) 
as brown solid (147 mg, 82%). 
1
H NMR (400 MHz, CDCl3): δ 7.51 (d, J = 8.0 Hz, 2 H), 7.48 (s, 1 H), 
7.29 (t, J = 7.8 Hz, 2 H), 7.08 (t, J = 7.4 Hz, 1 H), 5.39-5.30 (ovrlp, 2 H), 2.03-1.95 (ovrlp, 4 H), 1.71 
(qu, J = 7.5 Hz, 2 H), 1.38-1.22 (ovrlp, 20 H), 0.88 (t, J = 6.9 Hz, 3 H). 
13
C NMR (100 MHz, CDCl3): 
δ 171.9, 138.2, 130.1, 129.8, 128.9, 124.2, 120.1, 37.8, 32.0, 29.9, 29.8, 29.6, 29.41, 29.36, 29.2, 
27.31, 27.27, 25.8, 22.8, 14.2. HRMS (ESI): Calcd for C24H40NO [M+H]: 358.3104; Found: 
358.3093.  
 
 
 
 
3-((4-(tert-Butyl)phenyl)ethynyl)-N-(p-tolyl)cyclohexane-1-carboxamide (3p). Following the 
general procedure A, the title compound was prepared using methyl 3-((4-(tert-
butyl)phenyl)ethynyl)cyclohexane-1-carboxylate (diastereomeric ratio (d.r.) ~ 4.4:1, 1 equiv, 0.63 
mmol, 196 mg) and 4-nitrotoluene (1.5 equiv, 0.95 mmol, 130 mg), Ni(glyme)Cl2 (10 mol %, 13.9 
mg), and phen (10 mol %, 11.3 mg),  Zn (4 equiv, 2.52 mmol, 165 mg), TMSCl (2 equiv, 1.26 mmol, 
161 μL), and NMP (1.3 mL) under the reaction temperature of 120 oC. The crude product was purified 
by preparative TLC using hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (3p) as pale 
brown solid (118 mg, 50%). The diastereomeric ratio of the product was determined to be ~4:1 by GC 
analysis. 
1
H NMR (400 MHz, CDCl3): δ 7.40 (d, J = 8.3 Hz, 2 H), 7.34-7.25 (ovrlp, 5 H), 7.10 (d, J = 
8.0 Hz, 2 H), 2.52-2.43 (m, 1 H), 2.33-2.21 (ovrlp, 4 H), 2.05 (d, J = 12.6 Hz, 1 H), 1.97-1.85 (ovrlp, 2 
H), 1.76-1.34 (ovrlp, 5 H), 1.29 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 173.3, 150.9, 135.5, 134.0, 
131.4, 129.6, 125.3, 120.8, 120.1, 92.4, 80.9, 45.9, 35.9, 34.8, 32.5, 31.3, 30.0, 28.9, 25.2, 21.0. 
HRMS (ESI): Calcd for C26H32NO [M+H]: 374.2484; Found: 374.2487.  
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N-(4-(tert-Butyl)phenyl)-7-chloroheptanamide (3q). Following the general procedure A, the title 
compound was prepared using methyl 7-chloroheptanoate (0.50 mmol, 89 mg) and 1-(tert-butyl)-4-
nitrobenzene (0.60 mmol, 107 mg). The crude product was purified by preparative TLC using 
hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (3q) as viscous, deep brown oil (99 
mg, 67%). 
1
H NMR (400 MHz, CDCl3): δ 7.51 (s, 1 H), 7.44 (d, J = 8.2 Hz, 2 H), 7.31 (d, J = 8.2 Hz, 
2 H), 3.51 (t, J = 6.7 Hz, 2 H), 2.34 (t, J = 7.6 Hz, 2 H), 1.80-1.69 (ovrlp, 4 H), 1.48-1.36 (ovrlp, 4 H), 
1.29 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 171.4, 147.2, 135.5, 125.8, 119.8, 45.1, 37.5, 34.4, 32.5, 
31.5, 28.5, 26.8, 25.6. HRMS (ESI): Calcd for C17H27ClNO [M+H]: 296.1776; Found: 296.1767.  
 
 
 
 
N-(4-(tert-Butyl)phenyl)-5-morpholinopentanamide (3r). Following the general procedure A, the 
title compound was prepared using methyl 5-morpholinopentanoate (S2, 1 equiv, 0.50 mmol, 101 mg), 
1-(tert-butyl)-4-nitrobenzene (1.5 equiv, 0.75 mmol, 134 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), and 
phen (10 mol %, 9.0 mg) under the reaction temperature of 120 
o
C. The crude product was purified by 
preparative TLC using hexanes/CH2Cl2 (1:4) as an eluent to afford the title compound (3r) as brown 
solid (109 mg, 68%). 
1
H NMR (400 MHz, CDCl3): δ 7.77 (s, 1 H), 7.43 (d, J = 8.3 Hz, 2 H), 7.31 (d, J 
= 8.2 Hz, 2 H), 3.69 (t, J = 4.8 Hz, 4 H), 2.41 (t, J = 4.5 Hz, 4 H), 2.38-2.33 (ovrlp, 4 H), 1.74 (qu, J = 
7.6 Hz, 2 H), 1.55 (qu, J = 7.7 Hz, 2 H), 1.29 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 171.3, 147.2, 
135.5, 125.8, 119.8, 67.0, 58.6, 53.8, 37.3, 34.4, 31.4, 26.1, 23.6. HRMS (ESI): Calcd for C19H31N2O2 
[M+H]: 319.2386; Found: 319.2386.  
 
 
 
 
N-(4-(tert-Butyl)phenyl)-3-(2-hydroxyphenyl)propanamide (3s). Following the general procedure 
A, the title compound was prepared using methyl 3-(2-hydroxyphenyl)propanoate (1 equiv, 0.50 
mmol, 90 mg), 1-(tert-butyl)-4-nitrobenzene (1.3 equiv, 0.65 mmol, 116 mg), Ni(glyme)Cl2 (10 mol 
%, 11.0 mg), and phen (10 mol %, 9.0 mg) under the temperature of 140 
o
C. The crude product was 
purified by preparative TLC using hexanes/CH2Cl2 (1:1) as an eluent to afford the title compound (3s) 
as pale brown solid (62 mg, 42%). 
1
H NMR (400 MHz, CDCl3): δ 8.43 (br s, 1 H), 7.35 (d, J = 8.7 
Hz, 2 H), 7.32-7.28 (ovrlp, 3 H), 7.13-7.07 (ovrlp, 2 H), 6.90 (d, J = 7.7 Hz, 1 H), 6.84 (t, J = 7.4 Hz, 1 
H), 2.98 (t, J = 6.2 Hz, 2 H), 2.78 (t, J = 6.2 Hz, 2 H), 1.28 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 
172.6, 154.9, 148.0, 134.5, 130.7, 128.3, 127.8, 126.0, 120.7, 120.3, 118.0, 38.3, 34.5, 31.5, 24.7. 
HRMS (ESI): Calcd for C19H24NO2 [M+H]: 298.1802; Found: 298.1806. 
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5-(4-Chloro-3,5-dimethylphenoxy)-N-(p-tolyl)pentanamide (3t). Following the general procedure A, 
the title compound was prepared methyl 5-(4-chloro-3,5-dimethylphenoxy)pentanoate (S1, 0.50 mmol, 
135 mg) and 4-nitrotoluene (0.60 mmol, 82 mg). The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (3t) as pale brown solid (108 mg, 
62%). 
1
H NMR (400 MHz, CDCl3): δ 7.70 (s, 1 H), 7.37 (d, J = 8.0 Hz, 2 H), 7.07 (d, J = 8.0 Hz, 2 
H), 6.59 (s, 2 H), 3.89 (t, J = 5.7 Hz, 2 H), 2.38 (t, J = 6.8 Hz, 2 H), 2.31 (s, 6 H), 2.28 (s, 3 H), 1.89-
1.77 (ovrlp, 4 H). 
13
C NMR (100 MHz, CDCl3): δ 171.2, 156.8, 137.1, 135.5, 133.9, 129.5, 126.2, 
120.2, 114.5, 67.7, 37.1, 28.7, 22.5, 21.0, 20.9. HRMS (ESI): Calcd for C20H25ClNO2 [M+H]: 
346.1579; Found: 346.1571.  
 
 
 
 
5-(3-Cyanophenoxy)-N-(p-tolyl)pentanamide (3u). Following the general procedure A, the title 
compound was prepared using methyl 5-(3-cyanophenoxy)pentanoate (1 equiv, 0.50 mmol, 117 mg), 
4-nitrotoluene (1.5 equiv, 0.75  mmol, 103 mg), Ni(glyme)Cl2 (15 mol %, 16.6 mg), and phen (15 mol 
%, 13.6 mg) under the reaction temperature of 140 
o
C. The crude product was purified by preparative 
TLC using hexanes/CH2Cl2 (1:3) as an eluent to afford the title compound (3u) as deep brown solid 
(63 mg, 41%). 
1
H NMR (400 MHz, CDCl3): δ 7.38 (d, J = 8.3 Hz, 2 H), 7.34 (d, J = 9.0 Hz, 1 H), 
7.22 (d, J = 7.6 Hz, 2 H), 7.15-7.06 (ovrlp, 4 H), 4.00 (t, J = 5.2 Hz, 2 H), 2.43 (t, J = 6.4 Hz, 2 H), 
2.31 (s, 3 H), 1.96-1.83 (ovrlp, 4 H). 
13
C NMR (100 MHz, CDCl3): δ 170.7, 159.1, 135.4, 134.1, 
130.5, 129.6, 124.6, 120.0, 119.9, 118.9, 117.5, 113.3, 68.1, 37.2, 28.7, 22.3, 21.0. HRMS (ESI): 
Calcd for C19H21N2O2 [M+H]: 309.1608; Found: 309.1598.  
 
 
 
 
5-Oxo-5-phenyl-N-(p-tolyl)pentanamide (3v). Following the general procedure A, the title 
compound was prepared using methyl 5-oxo-5-phenylpentanoate (1 equiv, 0.50 mmol, 103 mg), 4-
nitrotoluene (1.5 equiv, 0.75 mmol, 103 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), and phen (10 mol %, 
9.0 mg) under the reaction temperature of 120 
o
C. The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (3:1) as an eluent to afford the title compound (3v) as brown solid (115 mg, 
82%). 
1
H NMR (400 MHz, CDCl3): δ 7.94 (d, J = 7.1 Hz, 2 H), 7.82 (s, 1 H), 7.54 (t, J = 7.4 Hz, 1 H), 
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7.45-7.39 (ovrlp, 4 H), 7.08 (d, J = 8.0 Hz, 2 H), 3.08 (t, J = 6.8 Hz, 2 H), 2.44 (t, J = 7.1 Hz, 2 H), 
2.28 (s, 3 H), 2.14 (qu, J = 7.2 Hz, 2 H). 
13
C NMR (100 MHz, CDCl3): δ 200.3, 171.0, 136.8, 135.5, 
133.8, 133.3, 129.5, 128.7, 128.2, 120.1, 37.5, 26.5, 20.9, 20.3. HRMS (ESI): Calcd for C18H20NO2 
[M+H]: 282.1497; Found: 282.1488.  
 
 
 
 
Methyl 4-(2-Oxo-2-(p-tolylamino)ethyl)benzoate (3w). Following the general procedure A, the title 
compound was prepared using methyl 4-(2-methoxy-2-oxoethyl)benzoate (0.50 mmol, 104 mg) and 4-
nitrotoluene (0.60 mmol, 82 mg). The crude product was purified by preparative TLC using 
hexanes/CH2Cl2 (3:1) as an eluent to afford the title compound (3w) as pale-brown solid (112 mg, 
79%). 
1
H NMR (400 MHz, CDCl3): δ 8.01 (d, J = 8.2 Hz, 2 H), 7.47 (s, 1 H), 7.37 (d, J = 7.9 Hz, 2 
H), 7.30 (d, J = 8.2 Hz, 2 H), 7.06 (d, J = 8.0 Hz, 2 H), 3.91 (s, 3 H), 3.71 (s, 2 H), 2.28 (s, 3 H). 
13
C 
NMR (100 MHz, CDCl3): δ 168.3, 166.9, 140.0, 135.1, 134.4, 130.3, 129.6, 129.4, 120.2, 52.3, 44.6, 
21.0. HRMS (ESI): Calcd for C17H18NO3 [M+H]: 284.1289; Found: 284.1272.  
 
 
 
 
N-(4-(tert-Butyl)phenyl)-6-morpholino-6-oxohexanamide (3x). Following the general procedure A, 
the title compound was prepared using methyl 6-morpholino-6-oxohexanoate (S3, 1 equiv, 0.50 mmol, 
115 mg), 1-(tert-butyl)-4-nitrobenzene (1.5 equiv, 0.75 mmol, 135 mg), Ni(glyme)Cl2 (10 mol %, 11.0 
mg), and phen (10 mol %, 9.0 mg) under the temperature of 120 
o
C. The crude product was purified by 
preparative TLC using hexanes/EtOAc (2:1) as an eluent to afford the title compound (3x) as viscous, 
deep brown oil (89 mg, 51%). 
1
H NMR (400 MHz, CDCl3): δ 8.46 (s, 1 H), 7.50 (d, J = 8.7 Hz, 2 H), 
7.30 (d, J = 8.7 Hz, 2 H), 3.66-3.60 (ovrlp, 6 H), 3.44 (t, J = 4.8 Hz, 2 H), 2.42-2.35 (ovrlp, 4 H), 1.77-
1.67 (m, 4 H), 1.29 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 171.6, 171.3, 146.9, 135.8, 125.7, 119.8, 
66.9, 66.6, 46.0, 42.0, 37.1, 34.4, 32.6, 31.4, 25.2, 24.4. HRMS (ESI): Calcd for C20H31N2O3 [M+H]: 
347.2335; Found: 347.2330.  
 
 
 
 
N
1
-(4-(tert-Butyl)phenyl)-N
6
-cyclohexyladipamide (3y). Following the general procedure A, the title 
compound was prepared using methyl 6-(cyclohexylamino)-6-oxohexanoate (S4, 1 equiv, 0.50 mmol, 
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121 mg) and 1-(tert-butyl)-4-nitrobenzene (1.2 equiv, 0.60 mmol, 108 mg), Ni(glyme)Cl2 (10 mol %, 
11.0 mg), and phen (10 mol %, 9.0 mg). The crude product was purified by recrystallization using 
CH2Cl2/hexanes as solvents to afford the title compound (3y) as white solid (138 mg, 77%). 
1
H NMR 
(400 MHz, CDCl3): δ 8.21 (s, 1 H), 7.49 (d, J = 8.5 Hz, 2 H), 7.31 (d, J = 8.5 Hz, 2 H), 5.73 (d, J = 8.2 
Hz, 1 H), 3.79-3.71 (m, 1 H), 2.39 (t, J = 5.5 Hz, 2 H), 2.21 (d, J = 5.9 Hz, 2 H), 1.89 (d, J = 11.9 Hz, 
2 H), 1.79-1.63 (ovrlp, 6 H), 1.62-1.57 (m, 1 H), 1.37-1.25 (ovrlp, 11 H), 1.21-1.07 (ovrlp, 3 H). 
13
C 
NMR (100 MHz, CDCl3): δ 172.1, 171.3, 147.1, 135.7, 125.8, 119.8, 48.4, 37.2, 36.5, 34.5, 33.3, 
31.5, 25.7, 25.2, 25.0, 24.9. HRMS (ESI): Calcd for C22H35N2O2 [M+H]: 359.2707; Found: 359.2680.  
 
 
 
 
N
1
-(4-(tert-Butyl)phenyl)-N
6
-(1-(4-fluorophenyl)-1H-indazol-5-yl)adipamide (3z). Following the 
general procedure A, the title compound was prepared using methyl 6-((1-(4-fluorophenyl)-1H-
indazol-5-yl)amino)-6-oxohexanoate (S5, 1 equiv, 0.50 mmol, 185 mg) and 1-(tert-butyl)-4-
nitrobenzene (1.5 equiv, 0.75 mmol, 134 mg), Ni(glyme)Cl2 (15 mol %, 16.5 mg), and phen (15 mol 
%, 13.5 mg) under the reaction temperature of 120 
o
C. The crude product was purified by 
recrystallization using CH2Cl2/hexanes as solvents to afford the title compound (3z) as off-white solid 
(112 mg, 46%). 
1
H NMR (400 MHz, DMSO-d6): δ 10.04 (s, 1 H), 9.81 (s, 1 H), 8.31 (s, 1 H), 8.28 (d, 
J = 1.4 Hz, 1 H), 7.81-7.74 (ovrlp, 3 H), 7.56 (dd, J = 9.1 Hz, J = 1.8 Hz, 1 H), 7.50 (d, J = 8.7 Hz, 2 
H), 7.41 (dd, 
3
JHH = 8.8 Hz, 
3
J HF = 8.8 Hz, 2 H), 7.28 (d, J = 8.7 Hz, 2 H), 2.40-2.32 (ovrlp, 4 H), 
1.70-1.62 (ovrlp, 4 H), 1.23 (s, 9 H). 
13
C NMR (100 MHz, DMSO-d6): δ 171.1, 170.9, 160.2 (d, 
1
JCF = 
242.0 Hz), 145.2, 136.7, 136.2 (d, 
4
JCF = 2.8 Hz), 135.6, 134.9, 133.7, 125.2, 125.1, 123.8 (d, 
3
JCF = 
8.5 Hz), 121.3, 118.9, 116.4 (d, 
2
JCF = 22.8 Hz), 110.4, 110.1, 36.32, 36.27, 33.9, 31.2, 25.0. HRMS 
(ESI): Calcd for C29H32FN4O2 [M+H]: 487.2504; Found: 487.2509. 
 
 
 
 
N-(2,5-Dimethoxyphenyl)cyclobutanecarboxamide (4a). Following the general procedure A, the 
title compound was prepared using ethyl cyclobutanecarboxylate (1 equiv, 0.50 mmol, 64 mg) and 
1,4-dimethoxy-2-nitrobenzene (1.5 equiv, 0.75 mmol, 137 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), 
and phen (10 mol %, 9.0 mg) under the reaction temperature of 120 
o
C. The crude product was 
purified by preparative TLC using hexanes/CH2Cl2 (1:1) as an eluent to afford the title compound (4a) 
as viscous brown oil (78 mg, 66%). 
1
H NMR (400 MHz, CDCl3): δ 8.18 (d, J = 3.1 Hz, 1 H), 7.71 (s, 
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1 H), 6.77 (d, J = 8.9 Hz, 1 H), 6.55 (dd, J = 8.8 Hz, J = 3.0 Hz, 1 H), 3.83 (s, 3 H), 3.78 (s, 3 H), 3.20 
(qu, J = 8.5 Hz, 1 H), 2.44-2.35 (m, 2 H), 2.28-2.20 (m, 2 H), 2.04-1.91 (m, 2 H). 
13
C NMR (100 
MHz, CDCl3): δ 173.3, 154.0, 142.0, 128.5, 110.8, 108.6, 105.7, 56.3, 55.9, 41.3, 25.5, 18.2. HRMS 
(ESI): Calcd for C13H18NO3 [M+H]: 236.1287; Found: 236.1287.  
 
 
 
 
N-(Naphthalen-1-yl)cyclopentanecarboxamide (4b). Following the general procedure A, the title 
compound was prepared using methyl cyclopentanecarboxylate (1 equiv, 0.50 mmol, 64 mg) and 1-
nitronaphthalene (1.5 equiv, 0.75 mmol, 130 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), and phen (10 
mol %, 9.0 mg) under the reaction temperature of 120 
o
C. The crude product was purified by 
preparative TLC using hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (4b) as deep 
brown solid (71 mg, 59%). 
1
H NMR (400 MHz, CDCl3): δ 7.96 (d, J = 7.5 Hz, 1 H), 7.87 (d, J = 7.7 
Hz, 1 H), 7.82 (d, J = 8.0 Hz, 1 H), 7.69 (d, J = 8.2 Hz, 1 H), 7.53-7.45 (ovrlp, 4 H), 2.88 (qu, J = 8.2 
Hz, 1 H), 2.10-2.01 (ovrlp, 4 H), 1.98-1.97 (m, 2 H), 1.74-1.63 (m, 2 H). 
13
C NMR (100 MHz, 
CDCl3): δ 175.0, 134.3, 132.6, 129.0, 127.2, 126.4, 126.0, 125.9, 125.7, 120.9, 120.5, 47.0, 30.8, 26.2. 
HRMS (ESI): Calcd for C16H18NO [M+H]: 240.1400; Found: 240.1376.  
 
 
 
 
tert-Butyl 3-((4-(tert-butyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate (4c). Following the 
general procedure A, the title compound was prepared using 1-(tert-butyl) 3-methyl pyrrolidine-1,3-
dicarboxylate (1 equiv, 0.50 mmol, 115 mg) and 1-(tert-butyl)-4-nitrobenzene (1.3 equiv, 0.65 mmol, 
116 mg) under the reaction temperature of 120 
o
C. The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (1:3) as an eluent to afford the title compound (4c) as viscous deep brown oil 
(84 mg, 48%). 
1
H NMR (400 MHz, CDCl3): δ 8.21 (s, 1 H), 7.45 (d, J = 8.4 Hz, 2 H), 7.30 (d, J = 8.2 
Hz, 2 H), 3.70-3.51 (ovrlp, 3 H), 3.35-3.28 (m, 1 H), 3.01 (br s, 1 H), 2.29-1.99 (ovrlp, 2 H), 1.46 (s, 9 
H), 1.28 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 170.8, 154.5, 147.4, 135.4, 125.8, 119.9, 119.8, 
79.7, 48.9, 45.60(44.65), 34.4, 31.4, 29.5(29.2), 28.6. HRMS (ESI): Calcd for C20H31N2O3 [M+H]: 
369.2154; Found: 369.2156.  
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N-(9H-Fluoren-2-yl)cyclohexanecarboxamide (4d). Following the general procedure A, the title 
compound was prepared using methyl cyclohexanecarboxylate (1 equiv, 0.50 mmol, 71 mg) and 2-
nitro-9H-fluorene (1.3 equiv, 0.65 mmol, 137 mg) under the temperature of 120 
o
C. The crude product 
was purified by preparative TLC using hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound 
(4d) as pale brown solid (90 mg, 62%). 
1
H NMR (400 MHz, CDCl3): δ 7.94 (s, 1 H), 7.72-7.68 (ovrlp, 
2 H), 7.51 (d, J = 7.4 Hz, 1 H), 7.37-7.33 (ovrlp, 2 H), 7.28-7.25 (ovrlp, 2 H), 3.88 (s, 2 H), 2.28-2.21 
(m, 1 H), 1.99 (d, J = 13.0 Hz, 2 H), 1.85 (d, J = 12.0 Hz, 2 H), 1.73-1.52 (ovrlp, 3 H), 1.35-1.28 
(ovrlp, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 174.4, 144.5, 143.3, 141.5, 138.0, 137.1, 126.9, 126.4, 
125.1, 120.2, 119.6, 118.5, 116.9, 46.8, 37.2, 29.9, 25.8. HRMS (ESI): Calcd for C20H22NO [M+H]: 
292.1701; Found: 292.1702.  
 
 
 
 
N-(3-Fluoro-4-methylphenyl)tetrahydro-2H-pyran-4-carboxamide (4e). Following the general 
procedure A, the title compound was prepared using methyl tetrahydro-2H-pyran-4-carboxylate (1 
equiv, 0.50 mmol, 72 mg) and 2-fluoro-1-methyl-4-nitrobenzene (1.3 equiv, 0.65 mmol, 101 mg) 
under the reaction temperature of 120 
o
C. The crude product was purified by preparative TLC using 
hexanes/CH2Cl2 (3:1) as an eluent to afford the title compound (4e) as brown solid (59 mg, 50%). 
1
H 
NMR (400 MHz, CDCl3): δ 7.67 (s, 1 H), 7.40 (d, J = 11.5 Hz, 1 H), 7.10-7.06 (ovrlp, 2 H), 4.04 (d, J 
= 8.2 Hz, 2 H), 3.41 (t, J = 11.5 Hz, 2 H), 2.53-2.44 (m, 1 H), 2.21 (s, 3 H), 1.98-1.76 (ovrlp, 4 H). 
13
C 
NMR (100 MHz, CDCl3): δ 172.9, 161.1 (d, 
1
JCF = 242.2 Hz), 137.0 (d, 
3
JCF = 10.6 Hz), 131.4 (d, 
3
JCF 
= 8.5 Hz), 120.7 (d, 
2
JCF = 17.5 Hz), 115.2 (d, 
4
JCF = 2.8 Hz), 107.5 (d, 
2
JCF = 26.9 Hz), 67.2, 43.2, 
29.3, 14.2, 14.1. HRMS (ESI): Calcd for C13H16FNO2 [M+H]: 238.1251; Found: 238.1230.  
 
 
 
 
N-([1,1'-Biphenyl]-3-yl)-1-methylcyclopropane-1-carboxamide (4f). Following the general 
procedure A, the title compound was prepared using ethyl 1-methylcyclopropane-1-carboxylate (1 
equiv, 0.35 mmol, 45 mg), 3-nitro-1,1'-biphenyl (1.3 equiv, 0.455 mmol, 91 mg), Ni(glyme)Cl2 (10 
mol %, 7.7 mg), and phen (10 mol %, 6.3 mg), Zn (4 equiv, 1.4 mmol, 92 mg), TMSCl (2 equiv, 0.70 
mmol, 89 μL), and NMP (0.70 mL) at 120 oC. The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (4f) as pale brown solid (61 mg, 
69%). 
1
H NMR (400 MHz, CDCl3): δ 7.79 (t, J = 1.9 Hz, 1 H), 7.60 (d, J = 1.6 Hz, 1 H), 7.58 (s, 1 H), 
7.53 (s, 1 H), 7.48 (dt, J = 7.8 Hz, J = 1.4 Hz, 1 H), 7.44-7.38 (ovrlp, 3 H), 7.36-7.31 (ovrlp, 2 H), 1.49 
(s, 3 H), 1.33 (q, J = 2.8 Hz, 2 H), 0.69 (q, J = 2.8 Hz, 2 H). 
13
C NMR (100 MHz, CDCl3): δ 173.4, 
142.2, 140.8, 138.6, 129.4, 128.8, 127.6, 127.3, 123.1, 118.9, 20.0, 16.8. HRMS (ESI): Calcd for 
C17H18NO [M+H]: 252.1390; Found: 252.1375.  
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N-(4-(tert-butyl)phenyl)pivalamide (4g).
19
 Following the general procedure A, the title compound 
was prepared using ethyl pivalate (0.50 mmol, 1 equiv, 65 mg), 1-(tert-butyl)-4-nitrobenzene (0.75 
mmol, 1.5 equiv, 134 mg), manganese (Mn, 5 equiv, 138 mg), iodotrimethylsilane (TMSI, 2 equiv, 
143 μL), Ni(glyme)Cl2 (15 mol %, 16.5 mg), and phen (15 mol %, 13.5 mg) at the reaction 
temperature of 140 
o
C. The crude product was purified by preparative TLC using hexanes/EtOAc (8:1) 
as an eluent to afford the title compound (4g) as pale brown solid (73 mg, 62%). 
1
H NMR (400 MHz, 
CD2Cl2): 7.43 (d, J = 8.2 Hz, 2 H), 7.36-7.30 (ovrlp, 3 H), 1.30 (s, 9 H), 1.28 (s, 9 H). 
13
C NMR (100 
MHz, CD2Cl2): 176.7, 147.5, 136.2, 126.1, 120.3, 39.8, 34.7, 31.5, 27.8.  
 
 
 
 
N-(4-(tert-butyl)phenyl)adamantane-1-carboxamide (4h). Following the general procedure A, the 
title compound was prepared using ethyl adamantane-1-carboxylate (0.50 mmol, 1 equiv, 104 mg), 1-
(tert-butyl)-4-nitrobenzene (0.75 mmol, 1.5 equiv, 134 mg), manganese (Mn, 5 equiv, 138 mg), 
iodotrimethylsilane (TMSI, 2 equiv, 143 μL), Ni(glyme)Cl2 (15 mol %, 16.5 mg), and phen (15 mol 
%, 13.5 mg) at the reaction temperature of 140 
o
C. The crude product was purified by preparative TLC 
using hexanes/EtOAc (8:1) as an eluent to afford the title compound (4h) as pale brown solid (136 mg, 
87%). 
1
H NMR (400 MHz, CD2Cl2): 7.46 (d, J = 8.6 Hz, 2 H), 7.38 (s, 1 H), 7.34 (d, J = 8.6 Hz, 2 H), 
2.09-2.05 (m, 3 H), 1.96-1.93 (m, 6 H), 1.80-1.72 (m, 6 H), 1.31 (s, 9 H). 
13
C NMR (100 MHz, 
CD2Cl2): 176.2, 147.4, 136.2, 126.0, 120.3, 41.8, 39.7, 36.9, 34.6, 31.5, 28.8. HRMS (ESI): Calcd for 
C21H30NO [M+H]: 312.2327; Found: 312.2327.  
 
 
 
 
N-(4-(tert-butyl)phenyl)tetradecanamide (4i). Following the general procedure A, the title 
compound was prepared using isopropyl tetradecanoate (0.50 mmol, 135 mg), 1-(tert-butyl)-4-
nitrobenzene (0.75 mmol, 134 mg), manganese (Mn, 5 equiv, 138 mg), iodotrimethylsilane (TMSI, 2 
equiv, 143 μL), Ni(glyme)Cl2 (15 mol %, 16.5 mg), and phen (15 mol %, 13.5 mg) at the reaction 
temperature of 140 
o
C. The crude product was purified by preparative TLC using hexanes/EtOAc (8:1) 
as an eluent to afford the title compound (4i) as pale brown solid (154 mg, 86%). 
1
H NMR (400 MHz, 
CD2Cl2): 8.14 (s, 1 H), 7.49 (d, J = 7.6 Hz, 2 H), 7.32 (d, J = 7.6 Hz, 2 H), 2.35 (t, J = 6.4 Hz, 2 H), 
1.71 (d, J = 6.6 Hz, 2 H), 1.37-1.25 (ovrlp, 29 H), 0.92 (d, J = 6.4 Hz, 3 H).        
13
C NMR (100 MHz, 
CD2Cl2): 172.3, 147.3, 136.3, 126.0, 120.3, 38.0, 34.7, 32.4, 31.6, 30.20, 30.18, 30.1, 30.0, 29.9, 29.8, 
26.3, 23.2, 14.4. HRMS (ESI): Calcd for C24H42NO [M+H]: 360.3262; Found: 360.3266. 
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N-(4-((4-Methoxyphenyl)amino)phenyl)benzamide (5a). Following the general procedure B, the 
title compound was prepared using methyl benzoate (1 equiv, 0.50 mmol, 68 mg) and 4-methoxy-N-
(4-nitrophenyl)aniline (1.2 equiv, 0.60 mmol, 147 mg). The crude product was purified by preparative 
TLC using hexanes/CH2Cl2 (3:1) as an eluent to afford the title compound (5a) as deep purple solid 
(105 mg, 66%). 
1
H NMR (400 MHz, CDCl3): δ 7.86 (d, J = 7.4 Hz, 2 H), 7.71 (s, 1 H), 7.55-7.44 
(ovrlp, 5 H), 7.05 (d, J = 8.4 Hz, 2 H), 6.93 (d, J = 8.4 Hz, 2 H), 6.86 (d, J = 8.3 Hz, 2 H), 5.49 (s, 1 
H), 3.80 (s, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 165.5, 155.2, 142.1, 136.0, 135.1, 131.6, 130.2, 
128.7, 126.9, 122.1, 121.7, 116.5, 114.7, 55.6. HRMS (ESI): Calcd for C20H19N2O2 [M+H]: 319.1447; 
Found: 319.1444.  
 
 
 
 
N-(3-Methoxy-4-methylphenyl)benzamide (5b).  
 
  (i) Synthesized from benzyl benzoate: Following the general procedure B, the title compound was 
prepared using benzyl benzoate (0.50 mmol, 106 mg) and 2-methoxy-1-methyl-4-nitrobenzene (0.60 
mmol, 109 mg). The crude product was purified by preparative TLC using hexanes/CH2Cl2 (3:1) as an 
eluent to afford the title compound (5b) as deep-brown solid (105 mg, 87%). 
1
H NMR (400 MHz, 
CDCl3): δ 8.22 (s, 1 H), 7.83 (d, J = 7.6 Hz, 2 H), 7.50-7.44 (ovrlp, 2 H), 7.39 (t, J = 7.5 Hz, 2 H), 7.03 
(d, J = 8.0 Hz, 1 H), 6.93 (d, J = 7.4 Hz, 1 H), 3.76 (s, 3 H), 2.17 (s, 3 H). 
13
C NMR (100 MHz, 
CDCl3): δ 166.0, 158.0, 137.1, 135.1, 131.7, 130.5, 128.7, 127.1, 122.9, 111.9, 103.3, 55.3, 15.9. 
HRMS (ESI): Calcd for C15H16NO2 [M+H]: 242.1181; Found: 242.1185.  
 
  (ii) Synthesized from phenyl benzoate: Following the general procedure B, the title compound was 
prepared using phenyl benzoate (0.50 mmol, 99 mg) and 2-methoxy-1-methyl-4-nitrobenzene (0.60 
mmol, 109 mg). The crude product was purified by preparative TLC using hexanes/EtOAc (6:1) as an 
eluent to afford the title compound (5b) as deep-brown solid (91 mg, 76%). Spectral and analytical 
data were identical to those reported for the same compound above. 
 
  (iii) Synthesized from 2-naphthyl benzoate: Following the general procedure B, the title compound 
was prepared using 2-naphthyl benzoate (0.50 mmol, 124 mg) and 2-methoxy-1-methyl-4-
nitrobenzene (0.60 mmol, 109 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc (6:1) as an eluent to afford the title compound (5b) as deep-brown solid (89 mg, 74%). 
Spectral and analytical data were identical to those reported for the same compound above. 
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4-(Dimethylamino)-N-(p-tolyl)benzamide (5c). Following the general procedure B, the title 
compound was prepared using ethyl 4-(dimethylamino)benzoate (1 equiv, 0.50 mmol, 97 mg), 4-
nitrotoluene (1.5 equiv, 0.75 mmol, 103 mg), Ni(glyme)Cl2 (15 mol %, 16.5 mg), and phen (15 mol %, 
13.5 mg). The crude product was purified by preparative TLC using hexanes/ EtOAc (4:1) as an eluent 
to afford the title compound (5c) as deep purple solid (64 mg, 50%). 
1
H NMR (400 MHz, CDCl3): δ 
7.86 (d, J = 7.4 Hz, 2 H), 7.71 (s, 1 H), 7.55-7.44 (ovrlp, 5 H), 7.05 (d, J = 8.4 Hz, 2 H), 6.93 (d, J = 
8.4 Hz, 2 H), 6.86 (d, J = 8.3 Hz, 2 H), 5.49 (s, 1 H), 3.80 (s, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 
165.5, 155.2, 142.1, 136.0, 135.1, 131.6, 130.2, 128.7, 126.9, 122.1, 121.7, 116.5, 114.7, 55.6. HRMS 
(ESI): Calcd for C20H19N2O2 [M+H]: 319.1447; Found: 319.1444.  
 
 
 
 
4-Amino-N-(4-(tert-butyl)phenyl)benzamide (5d). Following the general procedure B, the title 
compound was prepared using methyl 4-aminobenzoate (1 equiv, 0.50 mmol, 76 mg), 1-(tert-
butylmethyl)-4-nitrobenzene (1.3 equiv, 0.65 mmol, 117 mg), Ni(glyme)Cl2 (15 mol %, 16.5 mg), and 
phen (15 mol %, 13.5 mg). The crude product was purified by preparative TLC using hexanes/ EtOAc 
(1:1) as an eluent to afford the title compound (5d) as deep-brown solid (70 mg, 52%). 
1
H NMR (400 
MHz, CDCl3): δ 7.76 (s, 1 H), 7.69 (d, J = 8.2 Hz, 2 H), 7.53 (d, J = 8.3 Hz, 2 H), 7.35 (d, J = 8.2 Hz, 
2 H), 6.67 (d, J = 8.1 Hz, 2 H), 4.20 (br s, 2 H), 1.31 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 165.6, 
150.0, 147.2, 135.8, 129.0, 125.9, 124.5, 120.1, 114.3, 34.5, 31.5. HRMS (ESI): Calcd for C17H21N2O 
[M+H]: 269.1654; Found: 269.1660.  
 
 
 
 
N-(2,3-Dihydro-1H-inden-4-yl)-4-methoxybenzamide (5e). Following the general procedure B, the 
title compound was prepared using methyl 4-methoxybenzoate (0.50 mmol, 83 mg) and 4-nitro-2,3-
dihydro-1H-indene (0.65 mmol, 106 mg). The crude product was purified by preparative TLC using 
hexanes/CH2Cl2 (3:1) as an eluent to afford the title compound (5e) as pale brown solid (106 mg, 
79%). 
1
H NMR (400 MHz, CDCl3): δ 7.85-7.81 (ovrlp, 3 H), 7.64 (s, 1 H), 7.18 (t, J = 7.6 Hz, 1 H), 
7.04 (d, J = 7.2 Hz, 1 H), 6.96 (d, J = 8.4 Hz, 2 H), 3.85 (s, 3 H), 2.96 (t, J = 7.2 Hz, 2 H), 2.87 (t, J = 
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7.2 Hz, 2 H), 2.12 (qu, J = Hz, 2 H). 
13
C NMR (100 MHz, CDCl3): δ 165.1, 162.5, 145.4, 134.4, 
134.3, 129.0, 127.4, 127.3, 120.9, 119.0, 114.1, 55.6, 33.3, 30.2, 24.9. HRMS (ESI): Calcd for 
C17H18NO2 [M+H]: 268.1338; Found: 268.1340.  
 
 
 
 
4-(tert-Butyl)-N-(3-(methylthio)phenyl)benzamide (5f). Following the general procedure B, the title 
compound was prepared using methyl 4-(tert-butyl)benzoate (1 equiv, 0.50 mmol, 96 mg) and 
methyl(3-nitrophenyl)sulfane (1.2 equiv, 0.60 mmol, 102 mg). The crude product was purified by 
preparative TLC using hexanes/CH2Cl2 (4:1) as an eluent to afford the title compound (5f) as brown 
solid (124 mg, 83%). 
1
H NMR (400 MHz, CDCl3): δ 8.41 (s, 1 H), 7.77 (d, J = 8.2 Hz, 2 H), 7.66 (t, J 
= 2.0 Hz, 1 H), 7.38-7.36 (ovrlp, 3 H), 7.17 (t, J = 8.0 Hz, 1 H), 6.97 (d, J = 7.5 Hz, 1 H), 2.40 (s, 3 
H), 1.30 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 166.1, 155.4, 139.5, 138.8, 131.8, 129.2, 127.1, 
125.6, 122.4, 118.0, 117.1, 35.0, 31.2, 15.6. HRMS (ESI): Calcd for C18H22NOS [M+H]: 300.1422; 
Found: 300.1425.  
 
 
 
 
4-(tert-Butyl)-N-(3-cyano-4-methylphenyl)benzamide (5g). Following the general procedure B, the 
title compound was prepared using methyl 4-(tert-butyl)benzoate (1 equiv, 0.50 mmol, 96 mg), 2-
methyl-5-nitrobenzonitrile (1.5 equiv, 0.75 mmol, 122 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), and 
phen (10 mol %, 9.0 mg). The crude product was purified by preparative TLC using hexanes/CH2Cl2 
(1:1) as an eluent to afford the title compound (5g) as pale-brown solid (88 mg, 60%). 
1
H NMR (400 
MHz, CDCl3): δ 8.62 (s, 1 H), 7.95 (d, J = 2.3 Hz, 1 H), 7.80 (d, J = 8.5 Hz, 2 H), 7.75 (dd, J = 8.4 Hz, 
J = 2.3 Hz, 1 H), 7.41 (d, J = 8.5 Hz, 2 H), 7.21 (d, J = 8.4 Hz, 1 H), 2.46 (s, 3 H), 1.31 (s, 9 H). 
13
C 
NMR (100 MHz, CDCl3): δ 166.3, 155.8, 137.5, 136.7, 131.3, 130.8, 127.2, 125.7, 125.1, 124.0, 
118.0, 112.9, 35.0, 31.2, 19.9. HRMS (ESI): Calcd for C19H21N2O [M+H]: 293.1654; Found: 
293.1657.  
 
 
 
 
4-(tert-Butyl)-N-(4-(methylsulfonyl)phenyl)benzamide (5h). Following the general procedure B, the 
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title compound was prepared using methyl 4-(tert-butyl)benzoate (1 equiv, 0.50 mmol, 96 mg) and 1-
(methylsulfonyl)-4-nitrobenzene (1.3 equiv, 0.65 mmol, 131 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), 
and phen (10 mol %, 9.0 mg). The crude product was purified by preparative TLC using 
hexanes/CH2Cl2 (1:1) as an eluent to afford the title compound (5h) as off-white solid (102 mg, 62%). 
1
H NMR (400 MHz, CDCl3): δ 8.60 (s, 1 H), 7.88-7.80 (ovrlp, 6 H), 7.47 (d, J = 8.2 Hz, 2 H), 3.02 (s, 
3 H), 1.33 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 166.3, 156.2, 143.4, 135.1, 131.2, 128.6, 127.3, 
125.9, 120.3, 44.8, 35.1, 31.2. HRMS (ESI): Calcd for C18H22NO3S [M+H]: 332.1320; Found: 
332.1317.  
 
 
 
 
4-(tert-Butyl)-N-(4-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)benzamide (5i). Following the 
general procedure B, the title compound was prepared using methyl 4-(tert-butyl)benzoate (1 equiv, 
0.50 mmol, 96 mg) and tert-butyldimethyl(4-nitrophenethoxy)silane (1.5 equiv, 0.75 mmol, 211 mg), 
Ni(glyme)Cl2 (15 mol %, 16.5 mg), and phen (15 mol %, 13.5 mg). The crude product was purified by 
preparative TLC using hexanes/CH2Cl2 (3:1) as an eluent to afford the title compound (5i) as viscous 
brown oil (84 mg, 41%). 
1
H NMR (400 MHz, CDCl3): δ 7.86 (s, 1 H), 7.79 (d, J = 8.5 Hz, 2 H), 7.55 
(d, J = 8.4 Hz, 2 H), 7.47 (d, J = 8.5 Hz, 2 H), 7.19 (d, J = 8.4 Hz, 2 H), 3.79 (t, J = 7.0 Hz, 2 H), 2.80 
(t, J = 7.0 Hz, 2 H), 1.34 (s, 9 H), 0.88 (9 H), -0.00 (s, 6 H). 
13
C NMR (100 MHz, CDCl3): δ 165.7, 
155.4, 136.3, 135.5, 132.3, 129.8, 127.0, 125.8, 120.2, 64.6, 39.2, 35.1, 31.3, 26.1, 18.5. HRMS (ESI): 
Calcd for C25H38NO2Si [M+H]: 412.2672; Found: 412.2653.  
 
 
 
 
N-(4-(9H-Carbazol-9-yl)phenyl)-4-methylbenzamide (5j). Following the general procedure B, the 
title compound was prepared using methyl 4-methylbenzoate (1 equiv, 0.50 mmol, 75 mg), 9-(4-
nitrophenyl)-9H-carbazole (1.3 equiv, 0.65 mmol, 187 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), and 
phen (10 mol %, 9.0 mg). The crude product was purified by preparative TLC using hexanes/CH2Cl2 
(3:1) as an eluent to afford the title compound (5j) as deep-brown solid (120 mg, 64%). 
1
H NMR (400 
MHz, CDCl3): δ 8.14 (d, J = 7.8 Hz, 2 H), 7.98 (s, 1 H), 7.88 (d, J = 8.8 Hz, 2 H), 7.83 (d, J = 8.2 Hz, 
2 H), 7.55 (d, J = 8.7 Hz, 2 H), 7.43-7.38 (ovrlp, 4 H), 7.32 (d, J = 8.2 Hz, 2 H), 7.30-7.26 (m, 2 H), 
2.45 (s, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 166.1, 142.8, 141.1, 137.4, 133.8, 131.9, 129.6, 127.9, 
127.3, 126.1, 123.4, 121.7, 120.4, 120.0, 109.8, 21.6. HRMS (ESI): Calcd for C26H21N2O [M+H]: 
377.1654; Found: 377.1656.  
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N-(4-(tert-Butyl)phenyl)-4-fluorobenzamide (5k). Following the general procedure B, the title 
compound was prepared using ethyl 4-fluorobenzoate (0.50 mmol, 84 mg) and 1-(tert-butyl)-4-
nitrobenzene (0.65 mmol, 117 mg). The crude product was purified by preparative TLC using 
hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (5k) as off-white solid (116 mg, 86%). 
1
H NMR (400 MHz, CDCl3): δ 7.95 (s, 1 H), 7.85 (dd, 
3
JHH = 8.1 Hz, 
4
JCF = 5.6 Hz, 2 H), 7.53 (d, J = 
8.4 Hz, 2 H), 7.36 (d, J = 8.4 Hz, 2 H), 7.10 (dd, 
3
JHH = 8.1 Hz, 
3
JCF = 8.1 Hz, 2 H), 1.32 (s, 9 H). 
13
C 
NMR (100 MHz, CDCl3): δ 164.93 (d, 
1
JCF = 250.9 Hz), 164.91, 147.9, 135.3, 131.3 (d, 
4
JCF = 3.1 
Hz), 129.6 (d, 
3
JCF = 8.9 Hz), 126.0, 120.4, 115.9 (d, 
2
JCF = 21.8 Hz), 34.6, 31.5.  HRMS (ESI): Calcd 
for C17H18FNONa [M+Na]: 294.1270; Found: 294.1273.  
 
 
 
 
N-(4-(tert-Butyl)phenyl)-4-(trifluoromethyl)benzamide (5l). Following the general procedure B, the 
title compound was prepared using ethyl 4-(trifluoromethyl)benzoate (0.50 mmol, 102 mg) and 1-
(tert-butyl)-4-nitrobenzene (0.60 mmol, 117 mg). The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (5l) as brown solid (134 mg, 
84%). 
1
H NMR (400 MHz, CDCl3): δ 8.69 (s, 1 H), 7.85 (d, J = 7.9 Hz, 2 H), 7.55-7.52 (ovrlp, 4 H), 
7.31 (d, J = 8.4 Hz, 2 H), 1.30 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 165.2, 148.2, 138.3, 135.1, 
133.3 (q, 
2
JCF = 32.5 Hz), 127.8, 125.9, 125.6 (q, 
3
JCF = 3.7 Hz), 123.7 (q, 
1
JCF = 270.9 Hz), 120.8, 
34.5, 31.4. HRMS (ESI): Calcd for C18H19F3NO [M+H]: 322.1419; Found: 322.1422.  
 
 
 
 
N-(2,4-Dimethylphenyl)-3-methoxybenzamide (5m). Following the general procedure B, the title 
compound was prepared using ethyl 3-methoxybenzoate (1 equiv, 0.50 mmol, 90 mg), 2,4-dimethyl-1-
nitrobenzene (1.5 equiv, 0.75 mmol, 113 mg), Ni(glyme)Cl2 (10 mol %, 11.0 mg), and phen (10 mol 
%, 9.0 mg). The crude product was purified by preparative TLC using hexanes/CH2Cl2 (3:1) as an 
eluent to afford the title compound (5m) as pale-brown solid (76 mg, 60%). 
1
H NMR (400 MHz, 
CDCl3): δ 7.73 (d, J = 8.1 Hz, 1 H), 7.63 (s, 1 H), 7.45 (s, 1 H), 7.40-7.35 (ovrlp, 2 H), 7.09-7.04 
(ovrlp, 3 H), 3.86 (s, 3 H), 2.31 (s, 3 H), 2.28 (s, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 165.7, 160.1, 
136.7, 135.3, 133.2, 131.4, 129.9, 129.8, 127.5, 123.6, 118.8, 118.0, 112.7, 55.6, 21.0, 17.9. HRMS 
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(ESI): Calcd for C16H18NO2 [M+H]: 256.1338; Found: 256.1339.  
 
 
 
 
N-(3-(Trifluoromethyl)phenyl)-2-naphthamide (5n). Following the general procedure B, the title 
compound was prepared using methyl 2-naphthoate (0.50 mmol, 93 mg) and 1-nitro-3-
(trifluoromethyl)benzene (0.65 mmol, 124 mg). The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (5n) as off-white solid (122 mg, 
77%). 
1
H NMR (400 MHz, CDCl3): δ 8.33 (s, 1 H), 8.27 (s, 1 H), 7.98 (s, 1 H), 7.93-7.85 (ovrlp, 5 H), 
7.60-7.52 (ovrlp, 2 H), 7.47 (t, J = 8.0 Hz, 1 H), 7.40 (d, J = 7.8 Hz, 1 H). 
13
C NMR (100 MHz, 
CDCl3): δ 138.7, 135.1, 132.7, 131.7, 131.6 (q, 
2
JCF = 32.3 Hz), 129.8, 129.1, 129.0, 128.3, 128.1, 
128.0, 127.8, 127.2 (q, 
1
JCF = 270.6 Hz), 123.52, 123.46 (q, 
4
JCF = 0.8 Hz), 121.2 (q, 
3
JCF = 3.8 Hz), 
117.1 (q, 
3
JCF = 4.0 Hz). HRMS (ESI): Calcd for C18H13F3NO [M+H]: 316.0952; Found: 316.0943.  
 
 
 
 
N-(p-Tolyl)cinnamamide (5o). Following the general procedure B, the title compound was prepared 
using methyl cinnamate (0.50 mmol, 81 mg) and 4-nitrotoluene (0.65 mmol, 89 mg). The crude 
product was purified by preparative TLC using hexanes/CH2Cl2 (1:1) as an eluent to afford the title 
compound (5o) as off-white solid (102 mg, 86%). 
1
H NMR (400 MHz, CDCl3): δ 8.35 (s, 1 H), 7.70 
(d, J = 15.6 Hz, 1 H), 7.54 (d, J = 8.0 Hz, 2 H), 7.37 (d, J = 7.1 Hz, 2 H), 7.31-7.22 (ovrlp, 3 H), 7.07 
(d, J = 7.9 Hz, 2 H), 6.65 (d, J = 15.5 Hz, 1 H), 2.27 (s, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 164.6, 
142.0, 135.7, 134.8, 134.1, 129.8, 129.6, 128.8, 128.0, 121.4, 120.5, 21.0. HRMS (ESI): Calcd for 
C16H16NO [M+H]: 238.1226; Found: 238.1230.  
 
 
 
 
5-Methyl-N-(p-tolyl)nicotinamide (5p). Following the general procedure B, the title compound was 
prepared using methyl 5-methylnicotinate (0.50 mmol, 76 mg) and 4-nitrotoluene (0.60 mmol, 89 mg). 
The crude product was purified by preparative TLC using hexanes/CH2Cl2 (1:1) as an eluent to afford 
the title compound (5p) as off-white solid (88 mg, 78%). 
1
H NMR (400 MHz, CDCl3): δ 8.83 (s, 1 H), 
8.75 (s, 1 H), 8.48 (s, 1 H), 7.94 (s, 1 H), 7.49 (d, J = 8.0 Hz, 2 H), 7.11 (d, J = 8.0 Hz, 2 H), 2.32 
(ovrlp, 6 H). 
13
C NMR (100 MHz, CDCl3): δ 164.4, 152.6, 145.1, 136.0, 135.2, 134.6, 133.6, 130.7, 
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129.6, 120.8, 21.0, 18.4. HRMS (ESI): Calcd for C14H15N2O [M+H]: 227.1184; Found: 227.1188.  
 
 
 
 
N-(p-Tolyl)thiophene-3-carboxamide (5q). Following the general procedure B, the title compound 
was prepared using ethyl thiophene-3-carboxylate (0.50 mmol, 78 mg) and 4-nitrotoluene (0.60 mmol, 
89 mg). The crude product was purified by preparative TLC using hexanes/CH2Cl2 (5:1) as an eluent 
to afford the title compound (5q) as off-white solid (90 mg, 83%). 
1
H NMR (400 MHz, CDCl3): δ 
7.97-7.92 (ovrlp, 2 H), 7.49-7.46 (ovrlp, 3 H), 7.32 (dd, J = 5.0 Hz, J = 2.9 Hz, 1 H), 7.12 (d, J = 8.0 
Hz, 2 H), 2.31 (s, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 161.4, 138.0, 135.3, 134.3, 129.6, 128.7, 
126.7, 126.4, 120.7, 21.0. HRMS (ESI): Calcd for C12H12NOS [M+H]: 218.0646; Found: 218.0635.   
 
 
 
 
N-(p-Tolyl)furan-3-carboxamide (5r). Following the general procedure B, the title compound was 
prepared using ethyl furan-3-carboxylate (0.50 mmol, 70 mg) and 4-nitrotoluene (0.65 mmol, 89 mg). 
The crude product was purified by preparative TLC using hexanes/CH2Cl2 (5:1) as an eluent to afford 
the title compound (5r) as pale-brown solid (66 mg, 66%). 
1
H NMR (400 MHz, CDCl3): δ 8.14 (s, 1 
H), 8.00 (s, 1 H), 7.45 (d, J = 8.0 Hz, 2 H), 7.39 (s, 1 H), 7.08 (d, J = 8.0 Hz, 2 H), 6.74 (s, 1 H), 2.29 
(s, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 161.2, 145.3, 143.8, 135.2, 134.3, 129.5, 123.1, 120.9, 108.7, 
21.0. HRMS (ESI): Calcd for C12H12NO2 [M+H]: 202.0874; Found: 202.0863.  
 
 
 
 
1-Benzyl-N-(4-(tert-butyl)phenyl)-1H-indole-6-carboxamide (5s). Following the general procedure 
B, the title compound was prepared using methyl 1-benzyl-1H-indole-6-carboxylate (0.50 mmol, 126 
mg) and 1-(tert-butyl)-4-nitrobenzene (0.65 mmol, 116 mg). The crude product was purified by 
preparative TLC using hexanes/CH2Cl2 (3:1) as an eluent to afford the title compound (5s) as off-
white solid (96 mg, 50%). 
1
H NMR (400 MHz, CDCl3): δ 7.98 (s, 1 H), 7.95 (s, 1 H), 7.66 (d, J = 8.1 
Hz, 1 H), 5.57-7.50 (ovrlp, 3 H), 7.35 (d, J = 8.1 Hz, 2 H), 7.29-7.22 (ovrlp, 4 H), 7.08 (d, J = 6.3 Hz, 
2 H), 6.58 (s, 1 H), 5.31 (s, 2 H), 1.31 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 166.6, 147.3, 137.0, 
136.2, 135.8, 131.5, 131.2, 129.0, 128.4, 127.9, 127.0, 125.9, 121.0, 120.0, 117.6, 110.3, 102.2, 50.3, 
34.5, 31.5. HRMS (ESI): Calcd for C26H27N2O [M+H]: 383.2123; Found: 383.2126.  
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8-Methoxydibenzo[b,f][1,4]thiazepin-11(10H)-one (5t).  
 
  (i) 0.50 mmol. Following the general procedure B, the title compound was prepared using n-pentyl 2-
((4-methoxy-2-nitrophenyl)thio)benzoate (S6, 1 equiv, 0.50 mmol, 188 mg), Ni(glyme)Cl2 (10 mol %, 
11.0 mg), and phen (10 mol %, 9.0 mg) under the reaction temperature of 90 
o
C. The crude product 
was purified by preparative TLC using CH2Cl2 as an eluent to afford the title compound (5t) as brown 
solid (87 mg, 68%). 
1
H NMR (400 MHz, DMSO-d6): δ 10.61 (s, 1 H), 7.66 (dd, J = 7.3 Hz, J = 1.4 
Hz, 1 H), 7.50 (td, J = 7.6 Hz, J = 1.5 Hz, 1 H), 7.46-7.40 (ovrlp, 3 H), 6.80 (d, J = 2.7 Hz, 1 H), 6.73 
(dd, J = 8.6 Hz, J = 2.7 Hz, 1 H), 3.72 (s, 3 H). 
13
C NMR (100 MHz, DMSO-d6): δ 168.5, 160.3, 
141.1, 138.0, 136.8, 133.4, 131.9, 131.2, 131.1, 128.8, 119.9, 111.2, 108.6, 55.4. HRMS (ESI): Calcd 
for C14H12NO2S [M+H]: 258.0583; Found: 258.0576.  
 
  (ii) Gram scale. Following the general procedure B, the title compound was prepared using n-pentyl 
2-((4-methoxy-2-nitrophenyl)thio)benzoate (1 equiv, 2.93 mmol, 1.10 g), Ni(glyme)Cl2 (10 mol %, 64 
mg), and phen (10 mol %, 53 mg), Zn (4 equiv, 11.7 mmol, 767 mg), TMSCl (2 equiv, 5.86 mmol, 
748 μL), and NMP (12 mL) under the reaction temperature of 90 oC. Spectral and analytical data were 
identical to those reported for the same compound above.  
 
 
 
 
Dibenzo[b,f][1,4]oxazepin-11(10H)-one (5u). Following the general procedure B, the title compound 
was prepared using methyl 2-(2-nitrophenoxy)benzoate (0.50 mmol, 137 mg), Ni(glyme)Cl2 (10 mol 
%, 11.0 mg), and phen (10 mol %, 9.0 mg). The crude product was purified by preparative TLC using 
CH2Cl2 as an eluent to afford the title compound (6i) as brown solid (79 mg, 74%). 
1
H NMR (400 
MHz, CDCl3): δ 9.21 (s, 1 H), 7.96 (d, J = 7.4 Hz, 1 H), 7.53 (d, J = 7.3 Hz, 1 H), 7.31-7.22 (ovrlp, 3 
H), 7.18-7.10 (ovrlp, 3 H). 
13
C NMR (100 MHz, CDCl3): δ 167.9, 159.8, 151.1, 134.6, 132.1, 130.8, 
126.1, 126.0, 125.4, 125.3, 121.8, 121.5, 121.0. HRMS (ESI): Calcd for C13H10NO2 [M+H]: 
212.0712; Found: 212.0714.  
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7-Chlorodibenzo[b,f][1,4]oxazepin-11(10H)-one (5v). Following the general procedure B, the title 
compound was prepared using methyl 2-(5-chloro-2-nitrophenoxy)benzoate (0.50 mmol, 154 mg), 
Ni(glyme)Cl2 (10 mol %, 11.0 mg), and phen (10 mol %, 9.0 mg) under the reaction temperature of 90 
o
C. The crude product was purified by recrystallization (CH2Cl2/hexanes) as solvent to afford the title 
compound (5u) as deep-brown solid (65 mg, 53%). 
1
H NMR (400 MHz, DMSO-d6): δ 10.61 (s, 1 H), 
7.77 (d, J = 7.3 Hz, 1 H), 7.63 (t, J = 7.4 Hz, 1 H), 7.50 (s, 1 H), 7.38-7.31 (ovrlp, 2 H), 7.26 (d, J = 
7.9 Hz, 1 H), 7.17 (d, J = 8.4 Hz, 1 H). 
13
C NMR (100 MHz, DMSO-d6): δ 165.1, 158.1, 150.3, 134.3, 
131.1, 130.1, 128.0, 125.7, 125.5, 125.1, 122.4, 121.2, 120.4. HRMS (ESI): Calcd for C13H9ClNO2 
[M+H]: 246.0322; Found: 246.0322.   
 
 
 
 
8-Chlorodibenzo[b,f][1,4]thiazepin-11(10H)-one (6a). Following the general procedure B, the title 
compound was prepared using methyl 2-((4-chloro-2-nitrophenyl)thio)benzoate (0.50 mmol, 162 mg), 
Ni(glyme)Cl2 (10 mol %, 11.0 mg), and phen (10 mol %, 9.0 mg) under the reaction temperature of 90 
o
C. The crude product was purified by preparative TLC using hexanes/CH2Cl2 (1:1) as an eluent to 
afford the title compound (6b) as brown solid (61 mg, 47%). 
1
H NMR (400 MHz, DMSO-d6): δ 10.76 
(s, 1 H), 7.68 (dd, J = 7.4 Hz, J =1.4 Hz, 1 H), 7.57 (d, J = 8.3 Hz, 1 H), 7.54-7.44 (ovrlp, 3 H), 7.27 
(d, J = 2.0 Hz, 1 H), 7.21 (dd, J = 8.3 Hz, J = 2.1 Hz, 1 H). 
13
C NMR (100 MHz, DMSO-d6): δ 167.9, 
141.0, 137.3, 135.3, 133.7, 132.0, 131.2, 131.1, 128.9, 127.5, 124.9, 122.3. HRMS (ESI): Calcd for 
C13H9ClNOS [M+H]: 262.0093; Found: 262.0095.  
 
 
 
 
Dibenzo[b,f][1,4]thiazepin-11(10H)-one (6b). Following the general procedure B, the title compound 
was prepared using methyl 2-((2-nitrophenyl)thio)benzoate (0.50 mmol, 145 mg), Ni(glyme)Cl2 (10 
mol %, 11.0 mg), and phen (10 mol %, 9.0 mg) under the reaction temperature of 90 
o
C. The crude 
product was purified by preparative TLC using CH2Cl2 as an eluent to afford the title compound (6a) 
as brown solid (76 mg, 67%). 
1
H NMR (400 MHz, DMSO-d6): δ 10.69 (s, 1 H), 7.68 (dd, J = 7.1 Hz, 
J = 1.2 Hz, 1 H), 7.57-7.52 (ovrlp, 2 H), 7.50-7.42 (ovrlp, 2 H), 7.36 (t, J = 7.3 Hz, 1 H), 7.23 (d, J = 
7.7 Hz, 1 H), 7.14 (t, J = 7.3 Hz, 1 H). 
13
C NMR (100 MHz, DMSO-d6): δ 168.4, 139.9, 137.8, 136.3, 
132.5, 132.0, 131.4, 131.3, 129.8, 129.0, 128.9, 125.4, 123.2. HRMS (ESI): Calcd for C13H10NOS 
[M+H]: 228.0483; Found: 228.0485.  
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2-(2-Chlorophenyl)-N-(2-phenylbenzo[d]oxazol-5-yl)acetamide (6c). Following the general 
procedure A, the title compound was prepared using methyl 2-(2-chlorophenyl)acetate (1 equiv, 0.50 
mmol, 92 mg), 5-nitro-2-phenylbenzo[d]oxazole (1.2 equiv, 0.60 mmol, 144 mg), Ni(glyme)Cl2 (10 
mol %, 11.0 mg), and phen (10 mol %, 9.0 mg). The crude product was purified by preparative TLC 
using hexanes/CH2Cl2 (3:1) as an eluent to afford the title compound (6d) as deep brown solid (117 
mg, 65%). 
1
H NMR (400 MHz, CDCl3): δ 8.20 (d, J = 5.9 Hz, 2 H), 7.86 (s, 1 H), 7.54-7.47 (ovrlp, 3 
H), 7,45-7.31 (ovrlp, 7 H), 3.76 (s, 2 H). 
13
C NMR (100 MHz, CDCl3): δ 169.4, 164.0, 147.8, 142.6, 
134.7, 134.6, 131.7, 129.7, 129.4, 129.0, 127.81, 127.76, 127.1, 118.4, 111.9, 110.5, 44.9. HRMS 
(ESI): Calcd for C21H16ClN2O2 [M+H]: 363.0900; Found: 363.0898.  
 
 
 
 
N-(2-Phenylbenzo[d]oxazol-5-yl)benzamide (6d). Following the general procedure B, the title 
compound was prepared using methyl benzoate (1 equiv, 0.35 mmol, 48 mg), 5-nitro-2-
phenylbenzo[d]oxazole (1.3 equiv, 0.455 mmol, 109 mg), Ni(glyme)Cl2 (10 mol %, 7.7 mg), and phen 
(10 mol %, 6.3 mg), Zn (4 equiv, 1.4 mmol, 92 mg), TMSCl (2 equiv, 0.70 mmol, 89 μL), and NMP 
(0.70 mL). The crude product was purified by preparative TLC using hexanes/CH2Cl2 (3:1) as an 
eluent to afford the title compound (6e) as deep-brown solid (66 mg, 60%). 
1
H NMR (400 MHz, 
CDCl3): δ 8.23 (d, J = 4.6 Hz, 2 H), 8.12 (s, 1 H), 8.03 (s, 1 H), 7.89 (d, J = 6.7 Hz, 2 H), 7.65 (d, J = 
7.7 Hz, 1 H), 7.57-7.44 (ovrlp, 7 H). 
13
C NMR (100 MHz, CDCl3): δ 166.1, 164.1, 148.0, 142.7, 
135.01, 134.98, 132.0, 131.8, 129.0, 128.9, 127.8, 127.2, 127.1, 118.9, 112.3, 110.7.  HRMS (ESI): 
Calcd for C20H15N2O2 [M+H]: 315.1133; Found: 315.1135.  
 
 
 
 
N-(2-(4-Fluorophenyl)benzo[d]oxazol-5-yl)-2-phenylacetamide (6e). Following the general 
procedure A, the title compound was prepared using methyl 2-phenylacetate (1 equiv, 0.50 mmol, 75 
mg), 2-(4-fluorophenyl)-5-nitrobenzo[d]oxazole (1.3 equiv, 0.65 mmol, 168 mg), Ni(glyme)Cl2 (10 
mol %, 11.0 mg), and phen (10 mol %, 9.0 mg) under the reaction temperature of 120 
o
C. The crude 
product was purified by preparative TLC using hexanes/CH2Cl2 (3:1) as an eluent to afford the title 
compound (6f) as pale-brown solid (120 mg, 69%). 
1
H NMR (400 MHz, CDCl3): δ 8.22 (dd, 
3
JHH = 
8.7 Hz,
 4
JHF = 5.4 Hz, 2 H), 7.86 (d, J = 1.6 Hz, 1 H), 7.46-7.41 (ovrlp, 3 H), 7.38-7.34 (ovrlp, 4 H), 
7.25 (s, 1 H), 7.20 (dd, 
3
JHH = 8.6 Hz,
 3
JHF = 8.6 Hz, 2 H), 3.79 (s, 2 H). 
13
C NMR (100 MHz, CDCl3): 
δ 169.3, 165.0 (d, 1JCF = 251.4 Hz), 163.2, 147.9, 142.6, 134.8, 134.5, 130.0 (d, 
3
JCF = 8.9 Hz), 129.7, 
129.5, 127.9, 123.5 (d, 
4
JCF = 2.9 Hz), 118.3, 116.3 (d, 
2
JCF = 22.1 Hz), 111.9, 110.5, 44.9. HRMS 
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(ESI): Calcd for C21H16FN2O2 [M+H]: 347.1190; Found: 347.1196.  
 
 
 
 
(R)-3a-Ethyl-2,3,3a,4,5,7-hexahydrobenzo[2,3]azonino[6,5,4-hi]indolizin-6(1H)-one ((-)-
Rhazinilam, 6f).
16
 Following the general procedure A, the title compound was prepared using methyl 
(R)-3-(8-ethyl-1-(2-nitrophenyl)-5,6,7,8-tetrahydroindolizin-8-yl)propanoate
16
  (1 equiv, 0.0269 mmol, 
9.6 mg), Ni(glyme)Cl2 (20 mol %, 1.2 mg), phen (20 mol %, 1.0 mg), Zn (4 equiv, 0.108 mmol, 7 
mg), TMSCl (2 equiv, 0.0538 mmol, 7 μL), and NMP (0.3 mL) in a 2 mL-Teflon-screw cap test tube 
under the reaction temperature of 120 
o
C. The crude product was purified by preparative TLC using 
hexanes/CH2Cl2 (3:1) as an eluent to afford the title compound (6c) as off-white solid (4.7 mg, 59%). 
1
H NMR (400 MHz, CDCl3): δ 7.43 (dd, J = 7.2 Hz, J = 1.7 Hz, 1 H), 7.37-7.28 (ovrlp, 2 H), 7.21 (d, 
J = 7.7 Hz, 1 H), 6.56 (s, 1 H), 6.51 (d, J = 2.6 Hz, 1 H), 5.76 (d, J = 2.6 Hz, 1 H), 4.01 (dd, J = 11.8 
Hz, J = 5.5 Hz, 1 H), 3.79 (td, J = 12.1 Hz, J = 4.7 Hz, 1 H), 2.50-2.31 (m, 1 H), 2.31-2.17 (m, 1 H), 
1.98 (dd, J = 13.0 Hz, J = 7.8 Hz, 1 H), 1.89-1.82 (m, 1 H), 1.72 (td, J = 13.5 Hz, J = 3.1 Hz, 1 H), 
1.53-1.42 (ovrlp, 3 H), 1.30-1.20 (m, 1 H), 0.72 (t, J = 7.4 Hz, 3 H). HRMS (ESI): Calcd for 
C19H23N2O [M+H]: 295.1805; Found: 295.1795.  
 
 
 
 
N-(4-(tert-Butyl)phenyl)-6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinamide (6g). Following 
the general procedure B, the title compound was prepared using ethyl 6-((4,4-dimethylthiochroman-6-
yl)ethynyl)nicotinate (Tazarotene, 1 equiv, 0.10 mmol, 35 mg), 1-(tert-butyl)-4-nitrobenzene (1.5 
equiv, 0.15 mmol, 27 mg), Ni(glyme)Cl2 (15 mol %, 3.3 mg), and phen (15 mol %, 2.7 mg), Zn (4 
equiv, 0.40 mmol, 26 mg), TMSCl (2 equiv, 0.20 mmol, 26 μL), and NMP (0.30 mL). The crude 
product was purified by preparative TLC using hexanes/CH2Cl2 (3:1) as an eluent to afford the title 
compound (6g) as pale-brown solid (28 mg, 62%). 
1
H NMR (400 MHz, CDCl3): δ 9.05 (s, 1 H), 8.17 
(dd, J = 8.1 Hz, J = 2.3 Hz, 1 H), 8.05 (s, 1 H), 7.61-7.55 (ovrlp, 4 H), 7.39 (d, J = 8.7 Hz, 2 H), 7.23 
(dd, J = 8.2 Hz, J = 1.8 Hz, 1 H), 7.07 (d, J = 8.1 Hz, 1 H), 3.05 (d, J = 6.0 Hz, 2 H), 1.95 (d, J = 6.1 
Hz, 2 H), 1.33-1.32 (ovrlp, 15 H). 
13
C NMR (100 MHz, CDCl3): δ 163.4, 148.3, 146.4, 142.3, 135.6, 
135.D 2, 134.9, 130.6, 129.5, 129.1, 126.83, 126.77, 126.1, 120.4, 116.9, 93.1, 87.8, 37.2, 34.6, 33.1, 
31.5, 30.1, 23.4. HRMS (ESI): Calcd for C29H31N2OS [M+H]: 455.2157; Found: 455.2157.  
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N-(4-(tert-Butyl)phenyl)-2-(4-chloro-2-methylphenoxy)acetamide (6h). Following the general 
procedure A, the title compound was prepared using methyl 2-(4-chloro-2-methylphenoxy)acetate 
(MCPA-methyl, 1 equiv, 0.25 mmol, 54 mg), 1-(tert-butyl)-4-nitrobenzene (1.5 equiv, 0.375 mmol, 67 
mg), Ni(glyme)Cl2 (15 mol %, 8.3 mg), and phen (15 mol %, 6.8 mg), Zn (4 equiv, 1.0 mmol, 65.4 
mg), TMSCl (2 equiv, 0.50 mmol, 64 μL), and NMP (0.50 mL). The crude product was purified by 
preparative TLC using hexanes/CH2Cl2 (5:1) as an eluent to afford the title compound (6h) as off-
white solid (40 mg, 48%). 
1
H NMR (400 MHz, CDCl3): δ 8.20 (s, 1 H), 7.48 (d, J = 8.7 Hz, 2 H), 7.37 
(d, J = 8.7 Hz, 2 H), 7.18 (d, J = 2.2 Hz, 1 H), 7.14 (dd, J = 8.6 Hz, J = 2.4 Hz, 1 H), 6.75 (d, J = 8.6 
Hz, 1 H), 4.57 (s, 2 H), 2.33 (s, 3 H), 1.31 (s, 9 H). 
13
C NMR (100 MHz, CDCl3): δ 166.0, 154.0, 
148.2, 134.2, 131.1, 128.6, 127.15, 127.09, 126.1, 120.0, 113.2, 68.2, 34.6, 31.5, 16.4. HRMS (ESI): 
Calcd for C19H23ClNO2 [M+H]: 332.1417; Found: 332.1418.  
 
 
 
 
 
Screening Conditions for Reaction between Methyl Decanoate and Various 
Nitrobenzene-derived Intermediates. 
 
(i) General Considerations. For all intermediates, the reaction was performed with 7.5 mol% 
Ni(glyme)Cl2 / phen catalyst loading. 0.5 M ester (= 1 equiv) in 0.5 ml NMP was used. The reactions 
were performed with naphthalene as internal standard. Conversions and yields were analyzed by 
preparation of GC samples from the crude reaction mixtures and measuring the ratio of peak area of the 
ester and amide versus naphthalene. A peak area to concentration conversion factor of 0.87 was found 
through a calibration curve of isolated product amide versus naphthalene and this was used for 
determination of yield. Errors as large as 5 percentage points between independent experiments could 
generally be observed. 
 
(ii) Nitrosobenzene. Reactions were set up by varying the loading of zinc (2-4 equiv) and TMSCl (1-2 
equiv) systematically (Table S12). At the end of the reaction, 3ml water and 3 ml EtOAc were added 
and a GC sample was prepared with 50 µL from the top organic layer.  
 
(iii) N-Phenylhydroxyamine. Reactions were set up by varying the loading of zinc (2-4 equiv) and 
TMSCl (1-2 equiv) systematically (Table S13). At the end of the reaction, a few drops of the reaction 
mixture were added to 1 mL Et2O. The resulting suspension was shaken and filtered for GC sample 
preparation. The results show that starting with fewer equivalents than the standard conditions for the 
reaction with nitrobenzene leads to poorer yields. 
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 (iv) Aniline. Reactions were set up under conditions that might be relevant at a point in the reaction 
where a reasonable amount of aniline might have formed, including the addition of ZnCl2, as surrogate 
for the Zn(II) species that should form during the reaction and might influence the reactivity (Table 
S14). At the end of the reaction, a few drops of the reaction mixture were added to 1 mL Et2O. The 
resulting suspension was shaken and filtered for GC sample preparation. Despite a rather thorough 
screening of potentially relevant conditions, no yield higher than 45% was observed, ruling out aniline 
as an important intermediate. 
 
(v) Azoxybenzene. Reactions were set up by varying the loading of zinc (1-4 equiv) and TMSCl (0.09-
1 equiv) systematically (Table S15). At the end of the reaction, a few drops of the reaction mixture 
were added to 1 mL Et2O. The resulting suspension was shaken and filtered for GC sample preparation. 
 
 
 
 
Stoichiometric experiment of 4,4’-difluoroazobenzene 
 
In a nitrogen atmosphere glove box, 71.2 mg Zn (1.1 mmol, 2.2 eq), 219 mg Ni(glyme)Cl2 (1.0 mmol, 
2 eq), 180 mg 1,10-phenanthroline (1.0 mmol, 2 eq), 1.8 mmol NMP (dried by storing over 3Å 
molecular sieves), and 1.2 mg trimethylsilylchloride (0.015 mmol, 0.022 eq) were added to an oven 
dried scintillation vial. After stirring for 30 minutes, the mixture had turned from grey to black. 108 mg 
4,4’-difluoroazobenzene (0.49 mmol, 1 eq) and 16.6 mg α,α,α-trifluorotoluene (0.114 mmol) were then 
added to the above solution. After stirring the mixture for 2 hours at room temperature, 0.5 ml was 
filtered into an oven dried young’s NMR tube equipped with a DMSO-d6 capillary. The remainder of 
the mixture was heated to 90°C for three days. Another 0.5 ml was then filtered into another oven dried 
young’s NMR tube equipped with a DMSO-d6 capillary. To the remainder of the reaction mixture was 
added 80.8 mg methyl decanoate (0.434 mmol, 1.97 eq) and the resulting mixture was heated to 90°C 
over night. 20 µl of the reaction mixture was taken for a GC/MS sample and the remainder was filtered 
into an oven dried young’s NMR tube equipped with a DMSO-d6 capillary. 19F{H} NMR (376.3 
MHz), referenced to α,α,α-trifluorotoluene (-63.72 ppm, 1.00 integral) RT sample: -111.25 ppm 
(integral 1.15, free azobenzene), two merged broad peaks at -126.67 ppm and -129.42 ppm (combined 
integral 0.60). 3d 90°C sample: -131.59 ppm (integral 0.63) along with a few ill-defined peaks. Sample 
after reaction with ester: -122.45 ppm (integral 1.71, amidate), along with some ill-defined species. 
GC/MS analysis of the mixture after reaction with ester indicates the presence of the amide product and 
some aniline side-product, with a ratio of ~10:1 favoring the amide. 
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